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This study focused on the common 
sequence variation of the fat mass 
and obesity associated (FTO) gene.  It 
shows that also the individuals with 
a genetic predisposition to obesity 
benefit from lifestyle modification and 
lifestyle changes remain as an effec-
tive way to lose weight. Moreover, the 
gene expressions of FTO and serum 
amyloid A (SAA) were examined in 
subcutaneous adipose tissue of over-
weight and obese individuals with 
features of metabolic syndrome.
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ABSTRACT 
 
Obesity has reached epidemic proportions globally and is a major risk factor for type 2 diabetes and 
cardiovascular diseases (CVD). Obesity is anatomically characterised by an excessive adipose tissue 
mass. Adipose tissue is not simply a storage depot for energy. Instead, it is a complex, metabolically 
active tissue that secretes a variety of signalling molecules and pro-inflammatory factors that affect 
systemic metabolism. Acute-phase serum amyloid A (SAA) is one of proteins produced by the 
adipose tissue.  
An understanding of the genetic influences on obesity has also increased in recent years. FTO 
(fat mass and obesity associated) gene was the first locus discovered that was unequivocally 
associated with common form of human obesity. However, the mechanism by which this genetic 
variability is related to obesity is not known. 
The overall aim of the study was to investigate the associations of common sequence variation 
of FTO with obesity, related traits and CVD, and to examine the expressions of FTO and SAA in 
human subcutaneous adipose tissue.  
The obese subjects showed increased serum concentrations of SAA compared with normal 
weight control subjects, even though there were no differences in SAA expression. SAA expression, 
however, correlated with adiposity markers and also correlations between SAA and leptin were 
detected both in serum and at the gene expression level. The mechanism linking SAA and leptin is 
not yet clear. 
The FTO variant (rs9939609) was associated with BMI cross-sectionally and during the long-
term lifestyle intervention. In the DPS, the magnitude of weight reduction was greater in the 
intervention group, but the risk allele did not modify weight change in either of the groups. In men, 
the risk allele was associated, independently of BMI, with increased RANTES (Regulated on 
Activation, Normal T Cell Expressed and Secreted) and decreased high-density lipoprotein (HDL) 
concentrations. The male risk allele carriers were also at higher risk for CVD during the median 
follow-up of 10.2 years. This association was replicated cross-sectionally in the Metabolic Syndrome 
in Men study in the subgroup of men with type 2 diabetes. 
In conclusion, our data confirm the systemic low-grade state of inflammation in obese subjects. 
The FTO polymorphism may be one factor contributing to the variation of inflammatory markers. 
Based on the results from the DPS, it is unlikely that the common variant of the FTO markedly affects 
the magnitude of weight reduction achieved by lifestyle modification. Furthermore, we suggest that 
the variation in the FTO gene might be associated with the risk of CVD, particularly in men with 
abnormal glucose metabolism.  
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TIIVISTELMÄ 
 
Lihavuus on viime vuosikymmenten aikana yleistynyt jatkuvasti ja se lisää huomattavasti vaaraa 
sairastua moniin kansansairauksiin, kuten tyypin 2 diabetekseen ja sydän- ja verisuonisairauksiin. 
Lihavuudessa rasvakudoksen määrä on suurentunut ja rasvakudoksen on osoitettu toimivan, 
passiivisen energiavaraston ohella, aktiivisesti erittävänä endokriinisena elimenä. Rasvakudoksesta 
erittyy myös tulehdusta edistäviä välittäjäaineita, joiden oletetaan olevan yhteydessä lihavuuden 
liitännäissairauksiin.  
Vaikka lihavuuden nopea yleistyminen suurelta osin selittyy ympäristötekijöillä, on myös 
geenejä, jotka selkeästi vaikuttavat alttiuteen lihoa. FTO (fat mass and obesity associated) -geenin 
haitallisen muodon tiedetään lisäävän ihmisen lihomistaipumusta, mutta mekanismi on vielä 
tuntematon. 
Tässä tutkimuksessa selvitettiin tulehdusta edistävän seerumin amyloidi A:n (SAA:n) ja FTO:n 
ilmentymistä ihonalaisessa rasvakudoksessa ylipainoisilla henkilöillä, joilla oli metabolisen 
oireyhtymän piirteitä. Lisäksi selvitimme FTO-geenissä esiintyvän haitallisen, yhden nukleotidin 
sekvenssimuutoksen yhteyttä painoindeksiin, tulehdustekijöihin, seerumin lipideihin, 
painonmuutoksiin sekä sydän- ja verisuonitautien riskiin suomalaisessa diabeteksen 
ehkäisytutkimuksessa (DPS). 
Osoitimme ylipainoisilla henkilöillä seerumin SAA-pitoisuuden olevan suurempi kuin 
normaalipainoisilla henkilöillä. Emme kuitenkaan löytäneet eroa SAA-geenin ilmentymisessä 
ryhmien välillä. Uutena löydöksenä havaitsimme SAA:n korreloivan voimakkaasti rasvakudoksesta 
erittyvän leptiinin kanssa sekä seerumissa että geenien ilmentymisen tasolla. 
Tutkimuksemme DPS-aineistossa vahvisti FTO-geenin ja lihavuuden välisen yhteyden. Ne, 
joilla oli FTO-geenistä lihavuudelle altistava muoto, pystyivät kuitenkin pudottamaan painoaan yhtä 
tehokkaasti kuin muutkin. Miehillä havaitsimme FTO-geenin haitallisen muodon olevan yhteydessä 
tiettyjen tulehdustekijöiden kohonneisiin seerumipitoisuuksiin ja madaltuneeseen HDL-
kolesterolipitoisuuteen. Lisäksi totesimme miehillä 10.2 vuoden seurannan aikana saman FTO-
geenimuodon olevan yhteydessä kohonneeseen vaaraan sairastua sydän- ja verisuonisairauksiin. 
Tämä yhteys toistettiin myös Metabolinen Oireyhtymä Miehillä –tutkimuksessa henkilöillä, joilla oli 
tyypin 2 diabetes. 
Yhteenvetona voidaan todeta, että tutkimuksemme vahvisti lihavuuden olevan yhteydessä 
matala-asteiseen tulehdustilaan erityisesti SAA:n osalta. Lisäksi osoitimme FTO-geenin olevan 
yhteydessä lihavuuteen myös suomalaisessa aineistossa, mutta terveellinen, vähän energiaa sisältävä 
ruokavalio ja säännöllinen liikunta oli tehokas painonhallintakeino myös niille, joita FTO-geeni altisti 
lihomiselle. Tutkimuksemme perusteella FTO-geeni näyttäisi olevan yhteydessä paitsi 
lihomistaipumukseen, myös tulehdustekijöihin ja sydän- ja verisuonisairastuvuuden vaaraan 
erityisesti miehillä. 
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 1  INTRODUCTION 
 
The prevalence of obesity is increasing rapidly and, which has largely been attributed to 
increased dietary intake of high-energy food and physical inactivity. Obesity constitutes a 
major public health and clinical challenge since it is associated with an increased risk of such 
metabolic abnormalities as dyslipidaemia, hypertension, type 2 diabetes and cardiovascular 
diseases (CVD), all common features of the metabolic syndrome. An important predictor of 
obesity-associated morbidity and mortality is adipose tissue distribution, particularly 
abdominal obesity. 
Advances in adipose tissue biology over the past decades have led to an improved 
understanding of the mechanisms linking obesity with obesity-associated metabolic 
complications. Adipose tissue is not merely a passive energy storage depot, but it is a 
complex, metabolically active tissue that secretes a variety of signalling molecules, 
collectively known as adipokines. The first characterised molecule was leptin.  Since then, 
the number of adipokines has increased rapidly. Many of adipokines are involved in 
immune modulation and inflammatory responses and thus, obesity is nowadays 
characterised by a chronic, systemic low-grade state of inflammation. One of the recently 
discovered adipokines is serum amyloid A (SAA). SAA is an acute-phase protein, which 
was previously believed only to be expressed in, and released from, the liver in response to 
infection or inflammation. However, in obesity adipocytes appear to be a major site of its 
expression providing possible link between type 2 diabetes, CVD and inflammation. 
Even the environmental contribution to the obesity epidemic is apparent, the strong 
genetic component of obesity is also established in numerous studies. In 2007, genome-wide 
association studies (GWAS) led to the discovery of FTO (fat mass and obesity associated) 
gene as the first locus unequivocally associated with the common form of human obesity. 
FTO is a gene of unknown function. Therefore, more molecular and physiological studies 
are needed to explore the mechanisms and pathways that underlie the association with 
obesity. 
The aim of this work was to investigate the association of common sequence variation 
of FTO with obesity, related traits and CVD. In addition, the expressions of SAA and FTO in 
human subcutaneous adipose tissue were studied. 
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3 
2  REVIEW OF LITERATURE 
 
2.1 Obesity 
2.1.1 Definition and prevalence 
Obesity is a condition of excessive fat accumulation in adipose tissue as a consequence of 
imbalance between energy intake and energy expenditure. In the absence of a simple and 
accurate technique to measure body fat in the general population, body mass index (BMI) 
has been widely used and commonly accepted as a surrogate marker for excess body fat (1). 
BMI is calculated by dividing the individual’s weight in kilograms by the square of the 
individual’s height in meters (kg/m2). Overweight is defined as BMI 25.0 - 29.9 kg/m2, 
obesity 30.0 - 39.9 kg/m2 and morbid obesity higher than 40 kg/m2 (1,2).  
Although BMI does not differentiate between muscle and fat, it correlates well with 
body fatness and metabolic risk factors (3-8). Since the central fat distribution is more closely 
associated with unfavourable effects of obesity, waist circumference (WC) is used as a crude 
marker of intra-abdominal fat mass (9). Either singly or in combination with BMI, WC may 
have a stronger relation to some health outcomes than BMI (10). More accurate techniques to 
estimate adiposity include skin fold thickness, bioelectrical impedance, dual-energy X-ray 
absorptiometry (DEXA), under water weighing and imaging methods (e.g. computed 
tomography and magnetic resonance) (11), but they are also more laborious and expensive.  
The worldwide increase in the prevalence of obesity during the past decades has been 
widely documented (1). Although the latest reports from the United States indicate that the 
linear increase may have entered a period of relative stability, the prevalence of obesity (BMI 
≥ 30 kg/m2) continues to be high, exceeding 30% in most age groups in both genders (12). In 
Finland, nationwide epidemiological health surveys have been conducted since the mid-
1960s. The prevalence of obesity (BMI ≥ 30 kg/m2) was 8% in men and 17% in women aged 
15 years or older at the end of the 1960s and the early 1970s  (13). The latest report 
investigated 20-year changes in the Finnish population aged 30 years or older on the basis of 
two nationwide, representative samples (14). The prevalence of obesity has risen steeply 
(Figure 1) in all age and educational groups and in both genders being 20.7% for men and 
24.1% for women in the early 2000s.  The prevalence of severe obesity (BMI ≥ 35 kg/m2) was 
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4% in men and 7% in women. In addition, 0.8% of men and 1.9% of women had a BMI at 
least 40 kg/m2. Another Finnish data based on self-reported weight and height suggest that 
obesity has continued to increase among the 15–64 -year-old population also later in the 
2000s (15). 
Obesity causes or exacerbates a large number of health problems including impaired 
glucose tolerance, type 2 diabetes, hypertension, cardiovascular diseases (CVD), sleep 
apnoea, several cancer types, osteoarthritis, liver and gall bladder diseases (16). Thus, 
successful prevention or treatment of obesity has distinct health benefits that are of major 
public health importance. 
 
  
 
 
 
 
 
 
 
Figure 1. Mean body mass index (BMI) by gender in the Mini-Finland Health Survey (1978-1980) (17) , 
the Health 2000 (2000-2001) (18) and the National FINRISK (2007) (19) studies in the Finnish adult 
population.   
 
2.1.2 Factors predisposing to obesity 
Like many complex physiological conditions, obesity results from the interaction of genes 
and environmental factors. However, there is good agreement among experts that especially 
the current environment is driving the obesity epidemic (20).  
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Environmental factors 
Unfavourable changes in lifestyle over the past fifty years have led to what is now termed an 
“obesogenic” environment, i.e. reduced physical activity and easy access and consumption 
of energy-dense food.  
Trends in energy consumption are difficult to establish because of a variety of 
measurement issues. People under-report their energy intake, and higher BMI is associated 
with a greater degree of under-reporting (21). However, it is likely that increased energy 
intake has had a major impact on the development of obesity.  In the US population, the 
increase in caloric intake over the past 20 years is approximately 200 kcal/day (22). A very 
recent report shows that for the US population to return to the mean weights of the 1970s, 
the increased daily energy intake of 350 kcal for children and 500 kcal for adults would need 
to be reversed (23). In Europe, data from the MONICA study indicate that per capita energy 
supply correlates with prevalence of obesity (24). 
The effect of increased energy intake is compounded by sedentary lifestyles (25,26). 
Cultural changes have caused dramatic reduction in total daily physical activity. Most 
occupations no longer involve physical activity, and we rarely need to be physically active 
for transportation. Moreover, the development of television, computers, the internet, and 
video games has filled leisure time with sedentary pursuits. Recent studies also suggest that 
short sleep duration may be associated with the development of obesity from childhood to 
adulthood (367). 
 
Genetic risk factors 
From a genetic standpoint, humans living today are Stone Age hunter-gatherers displaced 
through time to a world that differs from that for which our genetic constitution was 
selected (27). Genes, that might have provided a survival advantage before may today 
predispose to obesity (28). Secondly, not everyone developes obesity in the present-day 
obesogenic environment, which highlights the multifactorial nature of the polygenic 
condition (29). 
Family and twin studies suggest that genetic factors contribute 40-70% to the 
interindividual variation in common obesity (30-32). Despite a relatively high heritability, 
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progress in identification of the genetic variants influencing predisposition to common form 
of obesity has been slow. Initial reports of promising associations between obesity and 
common variants in genes GAD2 (33-36), ENPP1 (37) and INSIG2 (38-41) had been reported, 
but the findings were not successfully replicated.  However, latest advancements in gene-
finding technology have led to rapid progress in understanding the genetic basis of common 
diseases. Genome-wide association (GWA) approaches cover the whole genome and have a 
great power to detect minor gene effects (42). The first three high-density GWAs for obesity-
related traits took place in 2007. Each confirmed the fat mass and obesity –associated gene 
(FTO) as the first gene incontrovertibly associated with common obesity and related traits, 
also in children (43-45).   
 
2.2  Role of white adipose tissue in low-grade inflammation 
Obesity can be characterised by adipocyte hypertrophy (increased size) and hyperplasia 
(increased number) (46). Based on very recent data, obese subjects are characterised by a 
higher total adipocyte number than lean individuals (47). This number is set during 
childhood and adolescence and stays approximately constant in adulthood. Approximately 
10% of the total fat cell pool is renewed by ongoing adipogenesis and adipocyte death 
annually at all adult ages and levels of BMI (47).  
Until a few decades ago, adipose tissue was regarded mainly as an inert reservoir 
storing triglycerides. Currently, it is considered a complex, highly active metabolic and 
endocrine organ (48,49). Adipose tissue produces a large variety of proteins (termed 
adipokines) regulating systemic processes, including food intake and nutrient metabolism, 
insulin sensitivity, stress responses, reproduction, bone growth and inflammation. Obesity- 
induced changes in adipose tissue metabolism and the development of metabolic 
disturbances are illustrated in Figure 2. 
The number of adipokines has expanded rapidly since the first characterised 
adipokine, the satiety factor leptin, in 1994 (50). The first pioneering observations 
underscoring the role of adipose tissue as a major site of production for pro-inflammatory 
molecules was conducted in 1993 by Hotamisligil et al. (51) who showed that white adipose 
tissue synthesises tumour necrosis factor α (TNF-α). More recently, the expression and 
secretion of a substantial number of factors linked to inflammation have been identified 
7 
including members of the cytokine family (interleukins), proteins secreted in the acute phase 
of inflammation and chemokines that seem to play a role in the obesity-associated 
infiltration of macrophages into adipose tissue (52-55).  
 
Figure 2. Obesity induced changes in adipose tissue metabolism and the development of metabolic 
disturbances. 
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An important aspect of adipose tissue endocrinology is the recognition that besides 
adipocytes, adipose tissue contains pre-adipocytes, macrophages, endothelial cells, 
fibroblasts, and leukocytes (48,55,56). This diverse composition renders adipose tissue an 
important mediator of inflammation and whole body metabolism.  
Adding to the complexity, the different fat depots (visceral and subcutaneous) are 
considerably heterogeneous in terms of adipokine secretion and expression patterns (57-60). 
Adipokines derived from visceral adipose tissue are secreted into the portal system and 
have direct access to the liver, whereas those derived from subcutaneous adipose tissue are 
secreted into the systemic circulation. Hence, the former may have relatively greater 
repercussions on hepatic metabolic function. 
The primary cause for obesity-induced inflammation is not yet fully understood. 
Macrophage infiltration and activation in the adipose tissue has provided one link between 
adipose tissue and inflammation (55). However, it remains to be investigated why 
macrophage infiltration is increased in adipose tissue. Some studies suggest that 
macrophage infiltration is for clearance of dead adipocytes in the adipose tissue (61,62). 
Furthermore, macrophage infiltration might be involved in the stimulation of angiogenesis 
during expansion of adipose tissue (63). 
A potential basis for the initiation of inflammation in obesity is also endoplasmic 
reticulum (ER) stress (64). Obesity may cause ER stress in adipose tissue due to excess lipid 
accumulation and disturbed energy metabolism.  ER stress activates a stress response 
signalling network termed the unfolded protein response (UPR) that drives protective but 
also apoptotic and inflammatory signalling cascades. A central mediator of inflammatory 
and stress responses is the nuclear factor (NF)-κB family of transcription factors (65). 
Another mechanism that could link obesity to altered production of adipokines is 
hypoxia present in adipose tissue (66-70). In the original report, it was suggested that as 
adipose tissue mass expands in obesity, clusters of enlarged adipocytes become distant from 
the vasculature, leading to local pockets of hypoxia (66). Hypoxia-inducible factor-1α (HIF-
1α) is induced in human adipocytes by hypoxia and is regarded as “a master hypoxia signal 
mediator” (71,72). Hypoxia in turn induces the gene expression of inflammatory markers in 
adipocytes and macrophages. The induced genes include TNF-α, interleukins (IL)-1, IL-6, 
monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1).  
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Furthermore, several signalling pathways have been proposed to explain the 
pathogenesis of obesity-associated inflammation (55,61,62,64). However, there is no unified 
theory yet for the metabolic and endocrinological dysfunctions of the white adipose tissue 
under obesity. 
 
2.2.1 Serum amyloid A (SAA) 
Serum amyloid A (SAA) is one of the major acute-phase proteins in humans. Its synthesis is 
markedly increased in response to infection, inflammation, injury and stress (73,74). The 
SAAs are precursors of amyloid A, a constituent of the amyloid fibrils that are involved in 
the pathogenesis of AA amyloidosis (368, 369). This form of amyloidosis is a complication 
that is associated with many inflammatory conditions (e.g. rheumatoid arthritis). Amyloid 
deposits with different biochemical structure have also been found in some chronic diseases, 
such as Alzheimer’s disease. Until recently, expression and secretion of SAA was thought to 
occur predominantly in the liver. However, currently it is known that adipose tissue is a 
major SAA expression site during the nonacute-phase conditions and adipose tissue mRNA 
and serum/plasma SAA levels are increased in obesity (75,76). Accumulating data also show 
positive correlations between SAA and adiposity measures, indicating a strong association 
with obesity (77-80). Furthermore, it appears that SAA expression is regulated by fat mass, 
since weight reduction has decreased SAA concentrations and its mRNA levels in the 
adipose tissue (75,78,79,81). 
SAA mRNA expression has been reported in both visceral and subcutaneous adipose 
tissues (75,77,78). Within adipose tissue, SAA gene is predominantly expressed and 
produced by mature adipocytes, not by cells of the stromavascular fraction (79). 
Accordingly, SAA protein is strongly related to adipocyte hypertrophy and preferentially 
produced by large adipocytes (82,83).  
The physiological role of SAA is not well understood. A proposed role of acute-phase 
SAA is that of an apolipoprotein, which displaces apolipoprotein A-1 from high-density 
lipoprotein (HDL). Thus, it might alter HDL function by reducing the clearance of excess 
cellular cholesterol (84). Inhibited reverse cholesterol transport might underlie the fact that 
increased concentrations of SAA are associated with elevated risk for cardiovascular events 
(85-88). Data also suggest that SAA can be a direct mediator in the development and 
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progression of atherogenesis and atherothrombosis (89). SAA may affect key events 
underlying acute coronary syndromes by contributing to endothelial dysfunction, 
promoting thrombosis, and enhancing leukocyte trafficking and activation (90).  
SAA is also a potential direct regulator of obesity-associated inflammation, and it may 
act as a paracrine factor to enhance cytokine production (79). It is a possible stimulus for the 
expression and release of interleukins in neutrophils (79,91-93). Furthermore, SAA directly 
stimulates the production of inflammatory cytokines in adipose tissue stromavascular 
fraction cells (79). Poitou et al. (82) have shown in vivo that SAA staining is highly correlated 
with macrophage infiltration in both fat depots of obese subjects, which suggests a link 
between SAA production and the presence of macrophages. Collectively, these findings 
implicate SAA as a local and systemic pro-inflammatory adipokine. Thus, SAA may provide 
a causal link between obesity, chronic systemic inflammation, and metabolic and 
cardiovascular consequences through stimulation of inflammatory cytokines locally in 
adipose tissue as well as at distant sites (79). However, additional studies are needed to 
better define the biology and clinical utility of SAA.  
 
2.3 Fat mass and obesity associated gene (FTO) 
Fat mass and obesity –associated gene (FTO) was originally cloned as a result of the 
development of the fused-toe (Ft) mutant mouse (94). Ft mouse mutation was created by 
insertional mutagenesis, resulting in the deletion of several hundred kilo base pair (kb) of 
genomic sequences, including fto, on mouse chromosome 8. The homozygous Ft mouse was 
embryonically lethal and showed abnormal development including left/right asymmetry 
(95). Heterozygous animals survived and were characterised by fused toes on the forelimbs 
and thymic hyperplasia, but were not reported to have altered body weight or adiposity (95). 
To date, FTO is still a gene of unknown function in an unknown pathway. In addition, FTO 
is the gene most robustly associated with common obesity thus far identified in humans (43-
45). 
FTO is a very large gene whose nine exons span more than 400 kb on chromosome 16 
(43). The most extensively studied single nucleotide polymorphism (SNP) is rs9939609 and it 
lies within the first intron of the FTO gene. Based on HapMap data, this polymorphism is 
highly correlated (r2 > 0.5) to ≥ 45 additional SNPs within a 47-kb region that covers parts of 
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the first two introns and exon 2 of FTO (43). Sequencing the chromosomes has not resulted 
in a clear candidate of functional variants in the FTO coding region, minimal splice sites, or 
the 3’-untranslated region (43,44). 
FTO is located close to a gene of unknown function, KIAA1005, which is transcribed in 
opposite direction (43). This may suggest that genetic variation affects a regulatory element 
for KIAA1005. However, Jacobsson et al. (96) have examined four SNPs, rs2111119, 
rs2302667, rs3213758 and rs4784320, in KIAA1005 and they could not detect association with 
obesity in a well-characterised cohort of children with severe obesity. 
  
2.3.1 Discovery as an obesity-susceptibility gene 
In 2007, Frayling et al. identified FTO through a genome-wide association study for type 2 
diabetes (43). A cluster of variants in the first intron of the FTO gene exhibited strong and 
highly significant association with type 2 diabetes. After adjusting for BMI, the association 
with type 2 diabetes was completely abolished, suggesting that FTO predisposes to type 2 
diabetes through an effect on BMI. Confirmation in 13 cohorts comprising more than 38 000 
individuals and a meta-analysis showed that the adults who were homozygotes for the risk 
allele weighed about 3 kg more and had a 1.67-fold increased risk for obesity compared with 
those who did not inherit a risk allele. This association was manifested by the age of 7 and 
reflected an increase in fat mass, especially subcutaneous fat and increased waist 
circumference (43). The frequency of the FTO risk alleles is high in populations of European 
descent: 63% carry at least one risk allele and 16% are homozygous. Although the 
population attributable risk for obesity (about 20%) and overweight (about 13%) was fairly 
high, the FTO variants explained only 1% of the variance in BMI. 
Shortly after this, Scuteri et al. (45) completed the first large-scale high-density 
genome-wide association study of BMI in more than 4000 Sardinians. In the initial analyses, 
variants in the FTO and platelet-type phosphofructokinase (PFKP) genes showed the 
strongest association, but only those in FTO were significantly replicated in European 
Americans and Hispanic Americans. Each risk allele increased BMI by about 0.10–0.13 
standard deviations (equivalent to about 0.40–0.66 kg/m2) and the risks for overweight and 
obesity by 1.18-fold and 1.32-fold, respectively.  
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In a third study, independent from the two previous studies but published at the same 
time, Dina et al. (44) identified FTO while testing for population stratification. They found 
several potentially functional SNPs in the FTO locus that were highly associated with early-
onset and severe obesity in both adults and children of European ancestry. 
Furthermore, genome-wide genotype data from a Finnish sample of 1161 type 2 
diabetes cases and 1174 normal glucose-tolerant controls replicated FTO-obesity association 
(97). The risk of T2D associated with the A allele of rs9939609 was increased by 
approximately 50%, but the association was abolished again when adjusted for BMI. 
After these original discoveries, the association between adiposity and SNPs in FTO 
has been confirmed in many genome-wide association studies (98,99) and the role of FTO as 
a gene predisposing to obesity especially in Caucasian populations has been established 
more firmly (Table 1) (100-103). Besides an association with BMI, overweight and obesity, 
FTO SNPs have also been associated with various obesity-related traits (Table 2) such as 
subcutaneous fatness (43,100), fat mass (43,100,103), ectopic fat stores in liver (104), hip (45) 
and waist circumference (103), HDL concentration (105), leptin levels (103), hs-CRP 
concentrations (106), but not with lean mass or body height (43,100,103).  
 
Of particular interest is the fact that the FTO variants do not seem to affect BMI or the 
risk of obesity consistently in African Americans (45), Chinese Hans (118), Japanese (113) or 
Oceanic populations (119). However, there are also studies of Chinese, Malay, Korean and 
Japanese populations as well as Canadians of South Asian origin and Inuit demonstrating 
associations between FTO polymorphisms and BMI or obesity with similar effect sizes 
compared with populations of European ancestry (120,124,132-136). Nonetheless, the 
evidence is more consistent in individuals with European descent. 
An explanation for the differences between the ethnic groups can be that underlying 
effect of FTO variation is only revealed in an obesogenic environment (112).  Alternatively, 
the effect of rs9939609 may be confined to those of European origin, or there may be rarer, 
population-specific variants more strongly associated with BMI (109,137). Moreover, in 
oceanic populations, the minor allele frequencies are less than in those of European origin 
(CEU, HapMap), and the patterns of linkage disequilibrium are also distinct. These 
observations may suggest that these population differences have arisen through 
13 
evolutionary divergence, perhaps as a result of some negative selection pressure against the 
FTO risk alleles in African and East Asian populations (138). 
 
Influence of FTO in childhood 
FTO loci identified through genome-wide association studies in adults have been tested for 
association with BMI and risk of obesity also in children. The original findings from the 
Avon Longitudinal Study of Parents and Children (ALSPAC) and from the Northern 
Finland Birth Cohort of 1966 (NFBC1966) suggested that the FTO genotype is not associated 
with fetal growth or birth weight (43). The ALSPAC data further revealed that FTO SNP 
rs9939609 is associated with changes in BMI and obesity in children by the age of seven, 
changes that persist into the prepubertal period and beyond (43). Later data have shown 
that the association between FTO and BMI and the risk of overweight becomes evident by 
the age of seven years (96,139), and the effect sizes observed in childhood persist into 
adolescence (137,139,140). Genetic variants in FTO have also shown biphasic changes in 
association with BMI and weight strengthening with age up to a peak at age 20 years, and 
then weakening with increasing adult age (141). The importance of FTO as an early onset 
obesity–susceptibility gene was also highlighted by a genome-wide association study in 
extremely obese young German individuals (102).                                                                                   
Although an association with birth weight has not been observed, Lopez-Bermejo et al.  
(142) found that already at the age of 2 weeks FTO SNPs are associated with increased 
ponderal index and weight, especially accretion of total and abdominal fat mass. In line with 
the previous studies, however, they did not find an association between rs9939609 SNP and 
birth weight.  
In a Swedish study, Jacobsson et al. (96) demonstrated that the FTO variant rs9939609 
was associated with obesity and BMI among girls, but not boys. Gender differences were 
also found in the associations of the FTO with obesity-related traits such as insulin 
sensitivity and plasma glucose.  
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2.3.2 Expression of FTO 
FTO gene expression profiles from human fetal and adult samples show that it is 
ubiquitously expressed in central and peripheral tissues (98,143,144). The highest relative 
levels have been found in the brain, particularly in the hypothalamus and cortex area (98). 
Similarly, studies in rodents have indicated that FTO mRNA expression is abundant in the 
brain, suggesting a central neuronal role for FTO (145-147). However, evidence for a 
peripheral role for FTO has also been found (98,143,148,149).  
In obesity, adipose tissue represents primary candidate to study the FTO expression 
and functional relevance. Studies that have compared the FTO expression between the lean 
and obese individuals have mainly shown greater expression levels for obese than for 
normal weight subjects (Table 3) (143,150,151). However, allele-spesific variation in the 
expression of FTO has not been found (143,149,152). Moreover, the heritability of FTO 
expression in adipose tissue and skeletal muscle has been shown to be low (149). 
The results on site-specific differences in FTO mRNA levels between subcutaneous 
and visceral adipose tissue are discordant (Table 3) (152,154). Differences between the 
depots can be due to number of factors differentiating these two depots, such as altered 
adipokine expression and lipolysis (155,156). FTO expression in the two depots correlates 
only modestly, which may suggest that expression is controlled locally (152). 
According to Wåhlen et al. (143), FTO mRNA in subcutaneous adipose tissue is largely 
derived from fat cells per se, rather than from the other cell types populating adipose tissue. 
They have also demonstrated in preadipocytes that FTO mRNA expression is induced at an 
early stage in the differentiation process and thereafter expression decreased during 
adipogenesis (143). Klöting et al. (152) found a negative correlation between FTO gene 
expression and BMI and body fat percentage. This may suggest that FTO expression is 
down-regulated in response to fat accumulation (152). This observation raises question 
whether the suppression of FTO expression aids the transformation of preadipocytes to fat-
laden mature adipocytes (157). On the other hand, it has been reported that the expression of 
FTO was moderately increased in adipocytes compared with preadipocytes and was 
substantially reduced in white adipose tissues of obese, diabetic db/db mice, indicating that it 
may play a role in adipocyte function, but not in adipogenesis (144). 
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Table 3. FTO expression studies. 
Reference  Study subjects Tissue sample(s) Findings
Grunnet et al. 
2009 (153) 
46 healthy men Skeletal muscle 
(vastus lateralis) 
-FTO expression was not influenced 
by the FTO rs9939609 genotype 
Grunnet et al. 
2009 (149) 
226 twins Skeletal muscle 
(n=159) 
Sc. adipose tissue 
(n=226) 
-FTO expression was regulated by 
age and sex in skeletal muscle and by 
age and BMI in adipose tissue 
 
Klöting et al. 
2008 (152) 
19 obese T2D 
and 36 obese 
NGT  subjects 
Sc. and visceral 
adipose tissue 
-FTO expression was 3-fold higher in 
sc. than in visceral adipose tissue 
Samaras et al. 
2009 (154) 
6 T2D and 10 
NGT  subjects 
Sc. and visceral 
adipose tissue 
-FTO expression was similar in both 
groups and there were no differences 
between the depots  
-In sc. adipose tissue, FTO expression 
correlated positively with TNF-α and 
NFκB expressions 
Villalobos-
Comparán et al. 
2008 (151) 
21 obese and 10 
lean subjects 
(Mexican) 
Sc. adipose tissue -Higher FTO expression in obese than 
in lean subjects 
Wåhlen et al. 
2008 (143) 
90 healthy 
women  
Sc. adipose and 
omental (n=18) 
tissue and  
-FTO expression was not influenced 
by the FTO rs9939609 genotype 
-FTO expression did not differ 
between the depots 
-Higher FTO expression in obese than 
in lean subjects in sc. adipose tissue 
Zabena et al. 
2009 (150) 
52 morbidly 
obese and 5 lean 
controls 
Sc. and visceral 
(n=35 obese) 
adipose tissue 
-Higher FTO expression in obese than 
in lean subjects in sc. adipose tissue 
-Among obese, FTO expression 
tended to be higher in sc. than in 
visceral adipose tissue 
NFκB= transcription factor nuclear factor-kappa-B; NGT=normal glucose tolerance; sc.=subcutaneous; TNF-
α=tumour necrosis factor-α; T2D=type 2 diabetes 
 
Recent findings suggest that FTO expression in human adipose tissue may play a role 
in the development of inflammation (154). Samaras et al. (154) demonstrated an association 
between the expressions of FTO and inflammatory markers, TNF-α and (transcription factor 
nuclear factor-kappa-B) NF-κB. FTO has also been shown to be expressed in macrophages 
and the expression is induced by inflammatory stimulants, γ-interferon (IFN-γ) and 
lipopolysaccharide (LPS) (144).  
Furthermore, FTO gene expression in subcutaneous and visceral depots appears to 
correlate positively with age (152). In skeletal muscle, FTO mRNA expression has been 
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shown to correlate negatively with fat and positively with glucose oxidation rates and with 
expression of genes involved in oxidative phosphorylation (153).  
Although FTO is widely expressed in central and peripheral human tissues, there is 
very scarce information on the function of this gene in different cell types. Thus, further 
investigations are warranted to elucidate the exact role of FTO and whether the changes in 
gene expression are secondary to obesity or causally related. 
 
2.3.3 Functions of FTO   
The discovery of FTO as an obesity-susceptibility gene has launched a series of studies to 
unravel the physiological mechanisms through which the risk alleles confer obesity.  
Two experiments, using bioinformatics analyses, have shown that FTO is a member of 
the non-heme dioxygenase superfamily that encodes a 2-oxoglutarate dependent nucleic 
acid demethylase. In vitro analyses show that FTO catalyses the demethylation of 3-
methylthymine in single-stranded DNA (145,158). However, the in vivo function of FTO is 
still largely unknown. The abundant FTO expression in the brain, in the areas governing 
energy balance has supported particularly a central neuronal role for FTO (98,146,147). 
Studies in humans have underpinned this hypothesis, because risk alleles of FTO have been 
associated with increased appetite and energy intake, and reduced satiety (159-163). 
Furthermore, in rodents FTO mRNA expression in the brain has been shown to be 
dependent on the energy state (146,147). Others have proposed a role for FTO through a 
decreased cerebrocortical insulin response (122). 
Studies in mice, however, have challenged the neuronal hypothesis and provided 
evidence for a different role of FTO (148). The absence of FTO in mice decreased lean body 
mass, but even moreso white adipose tissue, which was a consequence of increased energy 
expenditure and systemic sympathetic activation (148). Similarly Church et al. (164) found 
that a single mutation in the sequence coding for the mouse FTO protein decreased the 
functional activity of FTO and reduced fat mass and body weight. In white adipose tissue of 
mutant mice, gene expression profiling revealed increased expression of some fat and 
carbohydrate metabolism genes and an improved inflammatory profile (164).  
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A peripheral role for FTO was also suggested in a study indicating that FTO may be 
involved in regulation of body fat mass through lipolysis. A Swedish study conducted in 
healthy women showed that carriers of the risk allele had reduced lipolytic activity, 
independent of BMI (143).  
Fisher et al. (106) recently provided the first evidence that the FTO rs9939609 
polymorphism contributes to the variation in plasma hs-CRP levels independently of 
obesity. Consequently, their data suggest that the FTO variant not only increases the body 
weight, but may also enhance the inflammatory state of adipose tissue stores and increase 
systemic inflammation. Furthermore, they hypothesised that FTO might contribute to 
increased cardiovascular risk. 
 
Role in energy intake and whole body metabolism 
The hypothalamic expression of FTO suggests a potential role in the control of food intake 
and appetite (98,145,146). Furthermore, FTO expression is nutritionally regulated in the 
rodent hypothalamus (145,146,165). To date, accumulative data suggest also a link between 
FTO and eating behavior in humans.   
Children and adults carrying the FTO risk allele have been reported to have greater 
energy intake (Table 4) (159-163,166). Intake of all macronutrients have been shown to be 
greater in carriers of risk allele but especially so for fat intake (161). On the other hand 
Johnson et al. (167) did not find interaction between dietary energy density and FTO in a 
prospective setting. den Hoed et al. (168) suggested a role for FTO specifically in low 
postprandial responsiveness to hunger and satiety. However, studies using high-quality 
dietary data are warranted to further define how and to what degree the genetic risk by FTO 
can be modified by dietary factors (169). 
Major effects of FTO appear to be focused on energy intake since studies in humans 
have not confirmed an association with energy expenditure at rest or on physical activity 
(Table 4) (139,153,159,161,162,170,171). More precisely, Corpeleijn et al. (172) failed to find an 
association between FTO rs9939609 variant and fasting or fat-load-induced fat oxidation, 
which reduces the likelihood that FTO may influence obesity through an impaired capacity 
to utilise fatty acids for oxidation. In line with this, the FTO variant rs9939609 was not 
associated with postabsorptive and postprandial resting energy expenditure in a 
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randomised, multi-center European trial (173). However, two studies, one using the doubly 
labelled water method in children (161) and the second based on self-report data in adults 
(174), found evidence of greater activity-related energy expenditure among those carrying 
one or two copies of risk allele.  
Taken together, studies strengthen the possibility that energy intake plays a significant 
role in the relation between FTO and body weight. However, specific eating behavior 
phenotypes associated with this genetic polymorphism have not yet been identified. 
 
2.3.4 Studies carried out with FTO knock-out models 
Fischer et al. (148)  generated FTO-negative (FTO-/-) mice and mice carrying only one copy 
(FTO+/-) of the gene. They described a mouse knock-out model in which exons 2 and 3 of 
FTO were replaced by a neomycin STOP cassette. This cassette also deletes part of intron 1 
although not the position equivalent to the BMI-associated SNPs in human FTO. 
Homozygous FTO knock-out mice were viable but showed significant postnatal death 
before 4 weeks of age. By six weeks after birth, FTO-/- mice weighed on average 30–40% less 
than normal or FTO+/- mice. This reduction in weight was associated with a marked loss of 
white adipose tissue and lean mass. The leanness of FTO-deficient mice seemed to develop 
as a consequence of increased energy expenditure and systemic sympathetic activation, 
despite decreased spontaneous locomotor activity and relative hyperphagia. In fact, FTO-/- -
mice ate more in proportion to their body weight than normal mice. Moreover, on a high-fat 
diet, both groups of mutant mice gained much less weight than normal animals. Instead, 
FTO-/- mice used more energy without increasing physical activity. The authors suggested 
that this increased energy expenditure might be due to higher activity of the sympathetic 
nervous system. Supporting this view, they found enhanced circulating levels of adrenaline 
and noradrenaline (148). 
Not long thereafter, Church et al. (164) provided further functional evidence. They 
described the mice with a dominant missense mutation (I367F) in the FTO gene. The 
mutation resulted in a lean phenotype of reduced body weight and fat mass. Physical 
activity and food intake remained unchanged, but the metabolic rate increased. In the gene 
expression analysis they showed that fat and carbohydrate metabolism increased in mutant 
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mice and possessed an improved inflammatory profile. On a high-fat diet, mutant mice 
showed a lower fat mass than wild-type mice.  
Meyre et al. (175) determined whether FTO mutations are disproportionately 
represented in lean or obese humans. They sequenced the FTO coding region and intron-
exon boundaries in a large group of subjects with severe obesity and a similarly sized group 
of individuals with lifelong leanness. They discovered heterozygous, loss-of-function 
mutations in the FTO, but the mutations were found in both lean and obese subjects.  
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Table 4. Studies on the association of the FTO variation with energy intake and metabolism. 
Reference SNP Subjects 
 
Study design Association 
Cecil et al. 
2008 
 (161) 
rs9939609 97 Caucasian 
children 
Cross-sectional 
population-based 
-The A allele was associated with 
increased energy intake 
- An increase in resting energy 
metabolism in the A allele 
carriers was consistent with 
increased body mass 
Corpeleijn 
et al. 2009 
(172) 
rs9939609 722 
Caucasians  
Cross-sectional 
population-based 
-No association with energy 
expenditure or fat oxidation after 
a high fat load 
Do et al. 
2008  
(110) 
rs17817449 
rs1421085 
908 
Caucasians  
Cross-sectional 
population-based, 
family study 
-No BMI-independent association 
in energy intake or expenditure 
Hakanen et 
al. 2009 
(139) 
rs9939609 438 
Caucasian 
children 
Prospective, 
population-based  
intervention 
-No association with energy 
intake or physical activity index 
at age 15 
Haupt et al. 
2009  
(162) 
rs8050136 380 
Caucasians 
Lifestyle 
intervention 
program 
- Association with higher energy 
intake during dietary restriction 
among risk allele carriers 
-No association with energy 
expenditure 
Sonestedt et 
al. 2009 
(169) 
rs9939609 4839 
Caucasians 
Cross-sectional 
population-based 
- The obese AA carriers reported 
higher percentages of energy 
from fat and lower from 
carbohydrate 
Speakman 
et al. 2008 
(163) 
rs9939609 150 
Caucasians  
Cross-sectional 
population-based 
-Association with variation in 
energy intake 
-No association with basal 
metabolic rate or VO2max 
Tanofsky-
Kraff et al. 
2009 
(176) 
rs9939609 289 children 
with various 
racial-ethnic 
background 
Cross-sectional 
population-based 
 
-Subjects with risk alleles were 
more likely to report episodes of 
loss of control of eating and they 
consumed a greater percentage of 
energy from fat 
Timpson et 
al. 2008 
(160) 
rs9939609 3641 
Caucasian 
children 
Cross-sectional 
population-based 
-Subjects with risk allele 
consumed more fat and total 
energy  
Wardle et 
al. 2008 
(159) 
rs9939609 3337 
Caucasian 
children 
Cross-sectional 
population-based 
- Subjects carrying  AA genotype 
had lower satiety responsiveness 
Wardle et 
al. 2009 
(166) 
rs9939609 131 children Cross-sectional 
population-based 
- Subjects carrying risk allele 
showed higher consumption of a 
highly palatable food 
-No associations between 
genotype and any marker of 
physical activity. 
BMI= body mass index; VO2max=maximal oxygen consumption 
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2.4 Metabolic disorders related to obesity 
2.4.1 Metabolic syndrome  
 The term “metabolic syndrome” has developed to describe those individuals at increased 
risk of type 2 diabetes and CVD due to the metabolic disturbances commonly seen in 
overweight individuals with insulin resistance (175,177). The constellation of metabolic 
abnormalities includes obesity (particularly central obesity), raised blood pressure, elevated 
serum triglyceride levels, low serum HDL cholesterol levels, and hyperglycaemia. Over the 
past decade various diagnostic criteria for the metabolic syndrome have been proposed by 
different organisations, such as the International Diabetes Federation (IDF) (178) and the 
American Heart Association/National Heart, Lung, and Blood Institute (179). The IDF 
argued that central obesity, as assessed by waist circumference, should be an essential 
diagnostic criterion because of the strength of the evidence linking waist circumference and 
other metabolic co-morbidities. However, more recently several major organisations agreed 
on criteria in which waist circumference would not be an obligatory component (180).  Three 
abnormal findings out of five would qualify a person for the metabolic syndrome, and waist 
circumference would continue to be a useful preliminary screening measure (Table 5) (180). 
A single set of cut points would be used for all components except waist circumference, for 
which further work is required. In the interim, national or regional cut points for waist 
circumference can be used. 
 
Table 5. Criteria for clinical diagnosis of the metabolic syndromea (175). 
Measure Cut-off
Waist circumference Population- and country specific definitionsb  
Triglycerides ≥ 1.7 mmol/l* 
HDL cholesterol < 1.0 mmol/l (men); < 1.3 mmol/l (women)* 
Blood pressure > 130/85 mmHg* 
Fasting glucose ≥ 5.6 mmol/l* 
a3 out of 5 criteria should be met; be.g. IDF criteria for Europids: ≥94 cm (men) and ≥80 cm (women); 
*alternatively drug treatment 
 
2.4.2 Cardiovascular diseases  
Obesity, in particular abdominal obesity, is associated with an increased risk of CVD, 
especially coronary heart disease, peripheral vascular diseases, and stroke (181-188). On the 
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whole, overweight and obesity predispose to or are associated with numerous cardiac 
complications such as heart failure, coronary heart disease, sudden cardiac death, and atrial 
fibrillation (189). However, it is unclear and controversial which particular clinical measure 
of adiposity is the strongest predictor of CVD (190). Among the anthropometric variables, 
waist circumference is generally considered the most accurate indicator of CVD risk 
(191,192).  
Type 2 diabetes is an independent risk factor for cardiovascular morbidity and 
mortality, and in the past decades, obesity and diabetes have overtaken smoking, 
dyslipidaemia, and hypertension as risk factors for CVD (193-195). Individuals with diabetes 
are up to four times more likely than non-diabetic individuals to develop CVD (196-198). 
Furthermore, the proportion of people with diabetes who will die from cardiovascular 
causes is more than 70% (199).  To date, various mechanisms are proposed to contribute to 
accelerated diabetes-related complications.  
Chronic hyperglycaemia is the metabolic hallmark in type 2 diabetes. A number of 
studies have shown a strong relationship between the prevalence of vascular complications 
and raised levels of plasma glucose and/or glycated haemoglobin (HbA1c) (200-203). 
However, results regarding the efficacy of treatment of hyperglyceamia on cardiovascular 
events are conflicting (204-206). Several potential explanations for this paradox have been 
proposed. One explanation, the “common soil” hypothesis, proposes that medical control of 
hyperglycaemia alone does not reduce the risk of CVD because type 2 diabetes and CVD 
arise from a common antecedent pathophysiology (207,208).  
The cluster of plasma lipid and lipoprotein metabolism abnormalities may be one 
factor contributing to the excess risk of CVD in individuals with insulin resistance and type 
2 diabetes. Diabetic dyslipidaemia is characterised by high triglycerides, low HDL 
cholesterol and increased small dense LDL cholesterol concentrations (209-211). The lipid 
changes associated with type 2 diabetes are attributed to increased free fatty acid flux 
secondary to insulin resistance (212,213). In addition to pharmacologic agents, lifestyle 
changes are the cornerstones of dyslipidaemia management (214). The atherogenic lipid 
profile is partially corrected by sole control of the hyperglycemia, but abnormalities persist 
partly due to the effects of insulin resistance on lipoprotein metabolism (210,215). 
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A unifying mechanism for the initiation and progression of endothelial dysfunction in 
diabetic subjects might be hyperglycaemia-induced overproduction of reactive oxygen 
species (216-218). Furthermore, oxidatively modified atherogenic lipoproteins and advanced 
glycation endproducts are linked to oxidative stress in type 2 diabetes (219). However, the 
majority of data supporting the “oxidative stress theory” comes from in vitro studies, and 
evidence for a protective role of antioxidants is still conflicting (220). 
Data emerging over the past several years have established an additional role for the 
adipokines and low-grade inflammation in the development of insulin resistance and 
cardiovascular complications (221,222). The strongest pathogenic role in glucose metabolism 
has been suggested for TNF-α (223-225). Increased TNF-α concentration has been associated 
with degrees of early atherosclerosis (226) and several potential mechanisms for this 
association have been suggested (227). PAI-1 is another potent risk factor for CVD due to its 
pro-thrombotic properties (228-230). Adipose tissue is also considered a major extrahepatic 
source of angiotensinogen, which could contribute to the elevation of blood pressure and 
thus cardiovascular complications (231,232).  
Leptin regulates energy balance through a wide range of functions, including several 
that are important to cardiovascular health (233,234). Obesity-associated hyperleptinaemia 
has been linked to endothelial dysfunction and activation of the sympathetic nervous system 
(235-237). Additionally, recent evidence suggests that leptin released from perivascular 
adipose tissue may have deleterious effects on the underlying vasculature (238). However, 
the precise mechanisms are not known yet.  
Adiponectin is the only adipokine that is known to be down-regulated in obesity and 
in insulin resistance. Adiponectin may possess anti-atherogenic properties by inhibiting the 
expression of adhesion molecules and smooth muscle cell proliferation and suppressing the 
conversion of macrophages to foam cells (239,240). An anti-inflammatory role of adiponectin 
has also been reported (241).  
Furthermore, genetic factors influence the development of type 2 diabetes and CVD. 
Until GWAS, only a few common variants in peroxisome proliferator-activated receptor-
gamma (PPARG) (242), KCNJ11 (243) and transcription factor 7-like 2 (TCF7L2) (244) were 
shown to be associated with type 2 diabetes, but today there are at least 20 loci identified 
(245). Multiple genetic markers have also been associated with CVD. To date, however, the 
27 
 
utility of single genetic variants to improve cardiovascular risk prediction has shown mixed 
results, even for the most promising marker, located in the 9p21 region (246-248). 
 
2.5 Lifestyle modifications in the management of obesity  
The objectives of obesity management are a preferential reduction of abdominal fat, an 
amelioration of obesity-related health risks, an improvement in comorbidities and in quality 
of life, and a reduction in mortality rate (249). The changes in lifestyle factors are primarily 
directed to reduce energy intake and increase energy expenditure (250). The recipe for 
effective weight loss is a combination of motivation, physical activity, and caloric restriction 
keeping in mind that even a modest weight loss of 5–15% significantly reduces obesity-
related health risks (251). During the last decade, several studies performed in subjects with 
an impaired glucose tolerance have shown that lifestyle intervention is able to delay the 
development of type 2 diabetes (252-256). These studies used a combination of increased 
physical activity with dietary intervention.  
Obesity treatment should be individually tailored and the age, sex, degree of obesity, 
individual health risks, metabolic and psychobehavioral characteristics, and outcome of 
previous weight loss attempts should be taken into account. In the future, probably genetic 
factors will also be considered (251). 
Due to the chronic and relapsing nature of obesity, the cornerstone of lifestyle changes 
is weight loss maintenance, which requires a permanent balance between caloric intake and 
physical activity with lifelong compliance (257). Thus, an alternative strategy to address the 
obesity epidemic involves not focusing on weight loss, but promoting small changes in diet 
and physical activity to prevent further weight gain (258). 
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2.5.1 Diet 
In line with national dietary guidelines, a high-carbohydrate (≥55 % of daily energy intake) 
and low-fat (≤30 %) energy-deficient diets are generally recommended for weight 
management by health authorities and medical societies (249). A diet that creates a moderate 
caloric reduction of 500 to 1000 kcal/day generally evokes a weight loss of 0.5 to 1.0 kg per 
week.  
Moderate fat restriction is an effective method of lowering energy density and is 
associated with spontaneous weight loss (259). However, currently there is growing public 
interest and controversy whether reduced-fat or reduced-carbohydrate diets are best suited 
for weight loss. Recent studies have demonstrated that low- or moderate-carbohydrate, 
high-protein diets appear to induce as effective as low-fat, energy-restricted diets and 
actually the short-term weight loss may be greater with low-carbohydrate diet (260-264). 
However, typically the differences between the diets were no longer significant at one year 
of follow-up and long-term compliance is poor (261,264). Moreover, a greater weight regain 
has been reported with a low-carbohydrate diet than with a low-fat diet (261). Thus, most 
studies have concluded that the total energy deficit determines the weight loss and there is 
currently no evidence that clearly supports a superiority of one macronutrient composition 
for diets used for weight loss over a short period of time (262,265).  
However, there are number of safety concerns about the long-term use of low-
carbohydrate diet (250). These diets derive a large proportion of energy from protein and fat, 
which may have an unfavourable long-term impact on blood lipid concentrations, insulin 
resistance and on cardiovascular risk (266). Furthermore, low-carbohydrate diets are at 
greater risk of being nutritionally inadequate. Typically, these diets are low in fibre, thiamin, 
folate, potassium, calcium, magnesium, iron and vitamins A, E and B6 (267-269). 
Unquestionably, longer and larger studies are required to determine the long-term safety 
and efficacy of low-carbohydrate, high-protein, high-fat diets as compared with the 
generally recommended weight loss diet. 
Recently, diets based on the traditional Mediterranean dietary pattern (high in fruits, 
vegetables, nuts, whole grains and olive oil) are becoming popular for weight-loss purposes 
because of their additional health benefits, particularly regarding cardiovascular risk and 
glycaemic control (270-272).  
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2.5.2 Physical activity 
Although it is possible to lose weight with physical activity alone, the amount of physical 
activity required for substantial weight loss is well beyond what is feasible for most people 
in today's environment (273-276). Available evidence suggests that about 450 min/week or 
45-60 min/day of physical activity (<70% VO2max) is necessary to attain the recommended 0.5 
kg/week rate of weight loss.  
Accordingly, several government authorities and scientific organisations have issued 
guidelines for physical activity. Many of these guidelines recommend 30 min/day of 
moderate-intensity physical activity most days (249,277,278). Some guidelines recommend 
60 min/day of moderate-intensity physical activity to prevent weight gain and 60–90 
min/day of physical activity to maintain weight loss and prevent weight regain (277,279).  
Although physical activity does not appear to contribute markedly to weight loss, high 
levels of physical activity have been found to predict success in long-term maintenance of 
weight loss (280-282). Furthermore, physical activity protects against the loss of lean body 
mass, improves cardiorespiratory fitness, reduces obesity-related cardiometabolic health 
risks, and evokes sensations of well-being (251). 
 
2.5.3 Effect on inflammatory markers 
There are numerous studies indicating that decreasing energy intake and increasing physical 
activity may be effective for reducing overall systemic inflammation (specifically high-
sensitivity C-reactive protein [hs-CRP], TNF-a, IL-6 and leptin) and an increase in anti-
inflammatory markers (Table 6) (283-289). The greatest improvements in the inflammatory 
profiles are noted in those achieving drastic weight loss, e.g. due to gastric surgery. 
However, in the Finnish DPS a reduction in hs-CRP and PAI-1 concentrations have also  
been documented after the first year of intervention (289,290).  The weight loss-induced 
reduction of inflammatory markers in the circulation is often associated with a decrease in 
the production and gene expression of inflammatory markers in the adipose tissue (291-293). 
In future, more randomised, controlled intervention studies are required to accurately 
determine the time needed to maintain weight loss in order to benefit from improved 
inflammatory status in the long term. 
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When the weight loss diets of different macronutrient composition are compared with 
respect to inflammatory markers, no differences are apparent (294,295) with the exception of 
a low-glycaemic-load diet vs. a low-fat diet, where the former resulted in a marked decrease 
in serum hs-CRP concentration compared with the latter (296). Furthermore, very recent 
study suggests that the consumption of the diet high in saturated fatty acids results in 
increased expression of genes involved in inflammation processes in adipose tissue, whereas 
the diet rich in monounsaturated fatty acids leads to a more anti-inflammatory gene 
expression profile (297). Kallio et al. (298) have shown that intake for 12 weeks of cereal 
foods with differing postprandial insulin responses modulate the gene expression of 
inflammatory markers in both adipose tissue and circulating concentrations of serum, even 
in the absence of weight loss. However, more dietary interventions focusing on specific 
macronutrients and their effects on inflammation are needed to determine any mechanistic 
differences within macronutrients. 
Quite little is known of the adaptations of adipose tissue inflammatory gene profile to 
physical exercise alone, and results are inconsistent (299-303). Furthermore, since exercise 
training is generally associated with a reduction in fat mass, it is not well known whether 
the effect of exercise on inflammatory markers is due to the loss of fat mass or due to the 
other physiological adaptations to regular exercise.  
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2.5.4 Interactions with FTO  
The population attributable risk of common obesity associated with the FTO variant is relatively 
high, approximately 20%, in populations of European origin (43,44,100). Therefore, an important 
question is, whether the deleterious effects of some FTO polymorphisms on obesity can be 
suppressed by lifestyle factors, such as physical activity and diet.  
 
Diet 
FTO locus appears to confer a risk of obesity through increased energy intake rather than energy 
expenditure, suggesting that moderate and controlled restriction of energy intake may prevent 
FTO genotype–associated obesity (161).  To date number of intervention studies published is fairly 
limited, and an association between FTO variants and weight loss has not been found (104,309,310) 
suggesting that the variation in the FTO locus has no effect on the success of a lifestyle intervention 
program. However, Reinehr et al. (311) showed a trend towards lower weight loss in overweight 
children carrying risk allele of FTO rs9939609. 
Razquin et al. (312) found that the changes in the dietary macronutrient composition, but not 
in total energy intake, may interact with the FTO polymorphism. They demonstrated that 
Mediterranean-based diet, rich in mono- and polyunsaturated fat, confer to risk allele carriers 
some protection against body weight gain after three years of nutritional intervention. 
It is of potential importance to identify individuals with a genetic pattern that influences the 
response to weight reduction therapy, which would better enable individualised lifestyle advice to 
prevent obesity. Furthermore, conducting studies of the contributions of genetic variation to the 
risk of obesity during the dynamic process of weight gain is crucial, because once a stable weight is 
reached, the energy intake per unit of metabolic mass does not seem to differ between obese and 
lean people (313). Thus, especially long-term intervention trials are warranted. 
 
Physical activity 
Some observational studies have reported evidence of genotype-by-physical activity interactions 
on obesity, finding that the association between FTO genotype and obesity was strong in sedentary 
subjects but not among physically active individuals (Table 7) (103,170).  These observations could 
be interpreted to suggest that the increased risk of obesity can be attenuated through physical 
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activity, and high physical activity would be particularly beneficial in those genetically 
predisposed to obesity due to the FTO gene. In the near future, results from the Finnish DPS will 
also be reported as part of meta-analysis consisting of 40 cohorts. 
Andreasen et al. (103) published the first results in which the impact of the FTO rs9939609 
genotype was influenced by the habitual level of physical activity in a population-based study of 
Danish subjects with a mean BMI of 26 kg/m2. These subjects were divided according to self-
reported physical activity level into passive, light or medium and hard or very hard physically 
active, and stratified according to FTO genotype. The study showed that physically inactive 
homozygous FTO rs9939609 A-allele carriers had around two units higher BMI compared with 
inactive homozygous T-allele carriers. These findings were supported e.g. by Cauchi et al. (314) 
and Rampersaud et al. (170) for other FTO variants. Both showed that the differences in BMI were 
larger in physically inactive subjects while no difference was found at all in active subjects. 
However, a large study by Jonsson et al. (315) in Swedish adults did not find any interaction 
between rs9939609 and physical activity on BMI. The biggest differences between these studies are 
that the Swedish subjects were leaner (mean BMI of 24.3 kg/m2) than subjects in the other cohorts, 
and physical activity was only based on two categories, active or not active. However, another 
Danish study found no influence of physical activity on the association between rs9939609 
genotype and fat mass in men (171). Berentzen et al. (171) also investigated leisure time physical 
activity using self-administered questionnaires. Risk allele carriers of the rs9939609 variant did not 
seem to have lower physical activity levels than other genotypes. In line with this, a recent 
heritability study in twins did not show evidence of an interaction between the FTO variant and 
the environment (109). This was followed by a Finnish study in children (139), which also found no 
interaction between the FTO variant and leisure-time physical activity. These inconclusive findings 
with respect to gene-environment interactions may be due to small sample sizes and imprecise 
assessment of physical activity, and thus insufficient power to detect an interaction (316).  
Mitchel et al. (317) examined weight and cardiorespiratory fitness changes after 6 months of 
moderate intensity exercise in relation to FTO genotype. In a sample of white, postmenopausal, 
overweight and obese women, different genotypes of rs8050136 had the same magnitude of weight 
loss and thus, no genotype by exercise interaction was found. However, when exercising at, or 
above, the physical activity recommendations (8 kcal/kg/week or 12 kcal/kg/week) there was a 
significantly greater weight loss at 6 months among women who were homozygotes for the risk 
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allele. This would suggest that expending energy through moderate intensity exercise among 
postmenopausal women genetically predisposed to obesity is highly beneficial. In contrast, a study 
on previously sedentary but healthy Caucasians showed that homozygotes for the risk allele in the 
FTO gene locus were resistant to exercise-induced changes in fat mass (318). 
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Table 7. Interactions between FTO polymorphisms and physical activity. 
Reference  SNP Study subjects Study design Findings 
Andreasen et 
al.  2008 
(103) 
rs9939609 5554  
men and 
women 
Cross-sectional 
Population-based 
-Self-reported PA 
attenuated the effect of 
FTO variant on BMI 
Cauchi et al. 
2009 
(314) 
rs1421085 4762 Finnish 
adolescents and 
3167 French 
adults 
Cross-sectional, 
population-based 
-Self-reported PA 
attenuated the effect of 
FTO variant 
Hakanen et al. 
2009 
(139) 
rs9939609 438  
boys and girls 
Cross-sectional, 
population-baseda 
 
-No gene ×  self-reported 
leisure-time physical 
activity index interaction 
Jacobsson et 
al. 2009 
(319) 
 rs9939609 1153 men 32 year follow-up 
study beginning at 
the age of 50, 
population-based 
-Self-reported PA 
attenuated the effect of 
FTO variant on BMI (not 
significant)  
Jonsson et al. 
2009 
(315) 
rs9939609 2511 Finnish 
and 15 925 
Swedish men 
and women 
Cross-sectional, 
population-based 
-No gene ×  self-reported 
leisure-time physical 
activity interaction  
Karasawa et 
al. 2010 
(136) 
rs9939609 2639 
men and 
women 
Cross-sectional, 
population-based 
-Self-reported PA 
attenuated the effect of 
FTO variant on BMI 
Mitchel et al. 
2009 
(317) 
rs8050136 234  
women 
Lifestyle 
intervention with 6 
months of moderate 
intensity exercise  
-Homozygote carriers of 
risk allele had greater 
weight loss when 
exercising at, or above, the 
PA recommendations  
-No gene × exercise 
interaction  
Rampersaud 
et al. 2008 
(170) 
92 SNPs 
within 
FTO 
region 
702 
men and 
women 
Cross-sectional  
Old Order Amish -
population 
-PA (measured by 
accelerometry for 7 days) 
attenuated the effect of 
variant (rs1861868 and 
rs1477196) on BMI  
Rankinen et 
al. 2010 
(318) 
rs8050136 481 men and 
women  
20-week exercise 
intervention 
-Homozygotes for the risk 
allele were resistant to 
exercise-induced changes 
Vimaleswaran 
et al. 2009 
(320) 
rs1121980 20374  
men and 
women 
Cross-sectional, 
population-based 
-PA attenuated the effect of 
FTO variant on BMI and 
WC 
BMI= body mass index; PA =physical activity; WC=waist circumference  
aCross-sectional data from longitudinal Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) 
when children were 15 years old 
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3 AIMS OF THE STUDY 
 
 
A common allele in the FTO gene has been consistently associated with an increased risk of 
obesity. This study was carried out to investigate whether the FTO gene is associated with obesity, 
obesity-related phenotypes and CVD in the Finnish Diabetes Prevention Study (DPS). Due to the 
specialised function of adipose tissue, the gene expressions of FTO and SAA were also examined in 
overweight and obese individuals with features of metabolic syndrome. 
 
The specific aims were to: 
 
1. Investigate the low-grade inflammatory state by analysing SAA and leptin in subcutaneous 
adipose tissue and to evaluate the long-term impact of modest weight reduction on these 
adipokines (Study I). 
2. Examine whether the common variant of FTO is associated with obesity and long-term 
weight changes in individuals with impaired glucose tolerance participating in the Finnish 
DPS (Study II). 
3. Investigate the associations between FTO and CVD risk factors, including inflammatory 
markers and serum and lipoprotein lipids in the DPS (Study III). 
4. Study whether the FTO is associated with increased CVD risk in the DPS and in a 
population-based cross-sectional sample of Finnish men (METSIM Study) (Study III). 
5. Examine FTO gene expression in subcutaneous adipose tissue and in peripheral blood 
mononuclear cells (PBMCs) (Study IV). 
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4 SUBJECTS AND METHODS  
 
4.1 Study populations and study designs 
4.1.1 The Genetics of obesity and insulin resistance Study (Studies I and IV) 
Originally, the GENetics of OBesity and INsulin resistance (GENOBIN) study included seventy-
five 40- to 70-year old men and women (Table 8) (321,322). The subjects were overweight or obese 
(BMI 28–40 kg/m2) and they had impaired fasting glycaemia (IFG; fasting plasma glucose 
concentration 5.6–7.0 mmol/l) or impaired glucose tolerance (IGT; 2-h plasma glucose 
concentration 7.8–11.0 mmol/l), and at least two other features of the metabolic syndrome 
according to the Adult Treatment Panel III criteria (323) as modified by American Heart 
Association (324). Subjects were randomised to one of the following groups: a weight reduction 
group (n=28), an aerobic exercise group (n=15), a resistance training group (n=14), or a control 
group (n=18). Subjects were matched for age, gender, BMI, and the status of glucose metabolism 
(IFG, IGT, and type 2 diabetes). In the current study, only the weight reduction and control groups 
were studied further. In addition, 11 normal-weight healthy subjects (7 women and 4 men) were 
included as control subjects and they visited the laboratory once. 
The weight reduction group underwent a 12-week intensive weight reduction period during 
which they followed detailed instructions given by a clinical nutritionist, based on 4-day dietary 
records and an interview. Subjects were asked to maintain their habitual level of physical exercise. 
The weight loss period was followed by a weight maintenance period during the study weeks 12-
33. The minimum aim was to maintain weight loss that was achieved. Appointments with a 
nutritionist were organised if needed. The subjects in the control group were advised to continue 
their normal lifestyle during the study and to keep their diet and exercise habits unchanged during 
the whole 33-week study period. 
Biochemical and anthropometric measurements were performed at baseline, week 12 and at 
the end of the study at week 33.  Adipose tissue biopsy and 2h glucose tolerance test (OGTT) were 
performed at baseline and at the end of the study.  
The Research Ethics Committee, Hospital District of Northern Savo approved the study plan. 
All participants volunteered for the study and gave their written informed consent. 
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4.1.2 The Finnish Diabetes Prevention Study (Studies II-III) 
The Finnish Diabetes Prevention Study (DPS) is a multicentre study carried out in 1993-2000 in five 
participating centres in Finland, located in Helsinki, Kuopio, Oulu, Tampere and Turku (Table 8) 
(252). The main aim of the DPS was to assess the efficacy of an intensive and individually designed 
diet and exercise program to prevent or delay the onset of type 2 diabetes among high-risk 
individuals with IGT. The main inclusion criteria were BMI over 25 kg/m2, age 40 to 64 years and 
IGT based on the mean values of two consecutive OGTT measurements. IGT was defined 
according to the WHO criteria (1985) (325), i.e., as a plasma glucose concentration of 7.8-11.0 
mmol/l two hours after the oral administration of 75g of glucose with a non-diabetic fasting 
plasma glucose concentration (<7.8 mmol/l). Exclusion criteria included recent (within 6 months) 
cardiovascular event. A total of 522 subjects were randomly assigned either to the intensive diet 
and exercise counselling (n=265) or to the control (n=257) groups. Randomisation to the groups 
was stratified according to the clinic, gender and mean 2h plasma glucose concentration in OGTTs 
(7.8-9.4 mmol/l or 9.5–11.0 mmol/l). The subjects in the intervention group received individually 
tailored counselling on lifestyle, diet and exercise.  
The detailed goals of the intervention were:  1) to reduce weight of ≥5%; 2) to reduce total 
intake of fat to <30% of daily energy intake; 3) to reduce the intake of saturated fat to <10% of daily 
energy intake; 4) to increase fibre intake at least to 15 grams per 1000 kcal and 5) to exercise at 
moderate level for at least 30 minutes per day. The subjects in the control group were given 
general oral and written information about diet and exercise at baseline and at subsequent annual 
visits, but were offered no specific individualised programs. Medical history questionnaires, 
biochemical and anthropometric measurements were performed at baseline and at the annual 
visits. The most intensive intervention was carried out during the first year of the study, and the 
study was terminated after a mean follow-up of 3.2 years when the risk of diabetes had reduced by 
58% in the intervention group compared with the control group (252). However, the participants 
were thereafter invited to the open extended follow-up period.  
Cardiovascular morbidity and mortality data was collected from computerised register 
linkage to two nationwide health registers: the Hospital Discharge Register and Death Register, 
using the national personal identification number. The mean follow-up time was 10.6 years (326). 
Seventeen participants did not give their consent for the register linkages, and they were excluded 
from the analyses. Thus, the final number of participants is 490 in the Study III. The diagnoses for 
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hospitalisations have been coded according to the International Classification of Diseases (ICD) 
version 8 during 1967 to 1986, version 9 during 1987 to 1995, and version 10 since 1996. End points 
during follow-up were total mortality, and incident cardiovascular events (fatal and non-fatal), 
defined as the ICD 8 and 9 codes 401-449, and ICD 10 codes I10-I79. In both registers, the ICD 
codes for the diagnoses are assigned by the physician treating the patient. 
 The study protocol was approved by the Ethics Committee of the National Public Health 
Institute in Helsinki. All participants volunteered for the study and gave their written informed 
consent. 
 
4.1.3 Metabolic Syndrome in Men (Study III) 
The Metabolic Syndrome in Men study (METSIM) is a population-based cross-sectional sample of 
6214 men (Table 8) (327,328). The primary aim of this study with a total number of about 10 000 
men is to investigate the effect of genetic variation on the risk of type 2 diabetes and CVD. 
Subjects, aged from 45 to 70 years, were selected from the population register of the town of 
Kuopio in Eastern Finland. Participants had a one-day out-patient visit to the research unit, 
including an interview on the history of previous diseases and current drug treatment and an 
evaluation of glucose tolerance and cardiovascular risk factors. Fasting blood samples were drawn 
after 12 h of fasting followed by an OGTT. The WHO criteria (1999) (329) for IGT, IFG and type 2 
diabetes were used in the classification of the subjects, which was based on fasting plasma glucose 
and 2-h glucose concentrations in an OGTT. Altogether, 3587 subjects had normal glucose 
tolerance (NGT), 1730 had IFG and/or IGT, and 897 had type 2 diabetes. The data on the history of 
cardiovascular events were obtained by a personal interview.  
The study was approved by The Research Ethics Committee, Hospital District of Northern 
Savo, and it was in accordance with the Helsinki Declaration. All participants volunteered for the 
study and gave their written informed consent. 
 
4.1.4 The Functional Genomics and Nutrition Study (Study IV) 
Originally, 74 overweight or obese subjects were recruited to participate in the dietary 
intervention study (Table 8) (330,331). Originally, the objective was to test whether two different 
carbohydrate modification diets affect gene expression in subcutaneous adipose tissue. In the 
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thesis, however, we utilised only baseline data. The inclusion criteria were an age of 40-70 years, 
BMI of 26–40 kg/m2, and three of the criteria for the metabolic syndrome according to the National 
Cholesterol Education Program (2001) (323). At baseline, the subjects underwent a clinical 
investigation including an OGTT and anthropometric measurements. Fasting blood samples were 
drawn for the biochemical measurements and an adipose tissue biopsy was taken for the gene 
expression studies. 
The Research Ethics Committee, Hospital District of Northern Savo approved the study. The 
study was carried out according to the Declaration of Helsinki. All subjects volunteered to the 
study and gave their written informed consent. 
 
 
 
Table 8. Clinical characteristics of the study populations. 
 GENOBINa  
 
(Study I) 
DPSb
 
(Studies II and 
III) 
METSIM
 
(Study III) 
GENOBINa and 
FUNGENUT 
(Study IV) 
Gender (M/F) 37/38 172/350 6214/0 74/75 
Age (year) 60 ± 6.6 55.2 ± 7.1 58.7 ± 6.4 57.7 ± 7.0 
Weight (kg) 92.6 ± 12.8 86.1 ± 14.2 84.1 ± 13.9 92.3 ± 12.9 
BMI (kg/m2) 32.9 ± 2.8 31.2 ± 4.5 27.3 ± 4.2 32.4 ± 3.3 
Waist circumference 
(cm) 
109 ± 9 101 ± 11 99 ± 11 109 ± 9 
Blood pressure 
(mmHg) 
-systolic 
-diastolic 
 
 
137 ± 13 
89 ± 10 
 
 
138 ± 18 
86 ± 10 
 
 
139 ± 17 
88 ± 10 
 
 
139 ± 15 
89 ± 9 
Fasting serum 
cholesterol (mmol/l) 
 
5.3 ± 1.1 
 
5.6 ± 0.9 
 
5.3 ± 1.0 
 
5.6 ± 1.0 
Fasting HDL 
cholesterol (mmol/l) 
 
1.3 ± 0.2 
 
1.2 ± 0.3 
 
1.5 ± 0.4 
 
1.2 ± 0.3 
Fasting serum 
triglycerides (mmol/l) 
 
1.6 ± 0.8 
 
1.7 ± 0.8 
 
1.5 ± 1.1 
 
1.8 ± 1.0 
Fasting plasma 
glucose (mmol/l) 
 
6.4 ± 0.5 
 
6.1 ± 0.7 
 
6.0 ± 1.2 
 
6.3 ± 0.5 
Fasting 2-h plasma 
glucose (mmol/l) 
 
7.5 ± 2.1 
 
8.9 ± 1.5 
 
6.6 ± 2.5 
 
7.6 ± 2.1 
Data are mean±S.D. 
anormal weight subjects are excluded; bn=522 
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4.2. Methods 
        
4.2.1 Anthropometric measurements (Studies I-IV) 
Weight and height were measured with regularly calibrated devices in light indoor clothes, and 
BMI was calculated as kg/m2. Height was measured to the nearest 0.5 cm (0.1 cm in the 
FUNGENUT Study) and weight to 0.1 kg. Waist circumference was measured halfway between 
the lowest rib and iliac crest with a precision of 0.1 cm (Studies I and IV) or 0.5 cm (Studies II and 
III). Both weight and waist circumference were measured in a fasting state. Body composition was 
measured with bioelectrical impedance using a STA/BIA Body Composition Analyzer (Akern 
Bioresearch Srl, Firenze, Italy) (Studies I and IV).  
 
4.2.2 Biochemical measurements 
In all studies, glucose tolerance was determined by a 2h OGTT with a 75 g glucose dose after a 12-
hour overnight fast. Samples for plasma glucose and insulin concentrations were drawn at 0, (30) 
and 120 min.  
Studies I and IV. Plasma glucose concentration was measured with the hexokinase method 
(Thermo Clinical Labsystems, Vantaa, Finland) in the GENOBIN study and with the glucose 
dehydrogenase photometric method in the FUNGENUT study (Merck Diagnostica, Darmstadt, 
Germany).  Serum insulin was analysed with a chemiluminescence sandwich method (ACS 180 
Plus Automated Chemiluminescence System; Bayer Diagnostics, Tarrytown, NY) in both study 
populations. The frequently sampled intravenous glucose tolerance test was performed according 
to the minimal model method (332). The results were calculated with the Minimal Model 
Millennium software 6.02 (333). Total serum cholesterol and triglycerides, and HDL cholesterol 
after precipitation of apoprotein (apo) B were analysed with enzymatic methods (CHOD-PAP and 
GPO-PAP, Roche Diagnostics) on Kone Pro Clinical Chemistry Analyzer (Thermo Clinical 
Labsystems, Konelab, Espoo, Finland). Serum apo-AI concentration was measured 
immunoturbidometrically (Thermo Electron Corp, Konelab 20XTi, Vantaa, Finland). Hs-CRP was 
determined by Immage Immunochemistry System (Immulite 2000; DPC, 134 Los Angeles, CA). 
TNF-α and IL-6 concentrations were measured with a solid-phase high-sensitivity enzyme-linked 
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immunosorbent assay (Quantikine; R&D Systems, Minneapolis, MN). The SAA concentrations 
were measured with an ELISA kit (Biosource International, Camarillo, CA, USA). The serum leptin 
concentration was measured with a commercial RIA kit (Linco Research Inc., St Louis, MO, USA) 
and the adiponectin concentration was measured with an ELISA kit (R&D Systems Inc., MN, 
USA).  
Studies II and III. In the DPS, plasma glucose concentrations were determined at each centre 
locally according to standard guidelines. All other biochemical measurements were performed in 
the central laboratory of the Department of Biochemistry, National Public Health Institute, 
Helsinki. Serum insulin was determined with radioimmunoassay (Pharmacia, Uppsala, Sweden). 
Serum total cholesterol, triglycerides and HDL cholesterol were determined with an enzymatic 
assay method (CHOD-PAP, Boehringer Mannheim, Germany, Monotest). LDL cholesterol was 
calculated with the Friedewald formula (334). The serum concentration of hs-CRP was determined 
by a high-sensitivity latex-enhanced nephelometric assay (Dade Behring, Marburg, Germany). 
RANTES concentrations were assessed using an enzyme-linked immunosorbent assay (R&D 
Systems, Wiesbaden, Germany). 
In the METSIM study, the biochemical analyses were performed at the Clinical Research Unit 
in the University of Kuopio. Serum insulin was determined with an immunoluminometric method 
(Avidia Centaur IRI) on Advia Centaur Immunoassay System (both from Siemens Medical 
Solution Diagnostics, Tarrytown, NY, USA). The plasma glucose concentration was determined by 
the hexokinase method (Thermo Fisher Scientific, Vantaa, Finland). Serum total cholesterol and 
triglycerides were analysed with an enzymatic method and serum HDL and LDL were determined 
with direct enzymatic assays (KoneLab Systems Reagents). KoneLab 20XTi Clinical Chemistry 
Analyzer (Vantaa, Finland) was used for both glucose and lipid analyses. 
 
4.2.3 Adipose tissue biopsy (Studies I and IV) 
An adipose tissue biopsy (0.5–5 g) sample was collected as a needle biopsy under local anesthesia 
(lidocaine 10 mg/ml, without epinephrine) after a 12-hour overnight fast from the superficial 
abdominal subcutaneous adipose tissue lateral to the umbilicus. Adipose tissue samples were 
washed twice with GIBCO® phosphate buffered saline (PBS, Invitrogen, Carlsbad, CA) and stored 
in RNAlater (Ambion, Austin, TX) for 24 h at 4°C. After 24 h, RNAlater was removed and the 
samples were stored at -80 °C until used for RNA extraction.  
45 
 
A part of the adipose tissue sample was taken for cell size measurement. Adipocytes were 
isolated by the modification of Ohisalo et al. (335) of the method of Rodbell (336) in the presence of 
collagenase (0.5 mg/ml) under constant shaking at 2 Hz at 37°C. After 60 minutes cells were 
filtered through nylon cloth and washed three times with the same buffer without collagenase. 
Direct microscopic determination of the fat cell diameter was performed by placing an aliquot of 
cell suspension on the Bürker chamber and examining with light microscope (Olympus CH-2, 
Olympus, Tokyo, Japan). The diameters of 100–200 cells were estimated, and the median of the 
diameters was used to calculate fat cell size. 
 
4.2.4 Isolation of peripheral blood mononuclear cells 
The PBMCs were isolated from anticoagulated peripheral blood by density centrifugation using 
Lymphoprep reagent (Axis-Shield, Oslo, Norway) according to the manufacturer's instructions 
and thereafter stored in RNAlater RNA stabilising solution (Ambion, Austin, TX) according to the 
manufacturer's protocol in −80°C until used for RNA isolation. 
 
4.2.5 Genetics and gene expression 
4.2.5.1 DNA extraction and genotyping (Studies II-IV)                                                                      
Genomic DNA was prepared from peripheral blood leucocytes by the salting out method with a 
Puregene® DNA Purification Kit (Gentra Systems, Inc. MN) except for the METSIM study, where 
DNA was extracted from the whole blood using ABI PRISM® 6100 Nucleic Acid PrepStation 
(Applied Biosystems, Foster City, CA).  
In the DPS, the marker rs9939609 of the FTO was selected based on previous literature (43) 
and it was genotyped from 502 DNA samples for the Study II and from 490 for the Study III. The 
custom Golden Gate genotyping reagents and consumables were ordered from Illumina (San 
Diego, CA). In the METSIM Study and in the Study IV, rs9939609 were genotyped with TaqMan 
Allelic Discrimination Assays (Applied Biosystems, Foster City, CA). 
 
4.2.5.2 RNA isolation and cDNA synthesis (Studies I and IV) 
Total RNA from adipose tissue was extracted by using a TRIzol method followed by further 
purification with RNeasy Mini Kit columns according to the instructions provided by the 
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manufacturers (Invitrogen, Carlsbad, CA and Qiagen, Valencia, CA). RNeasy Mini Kit was also 
used for total RNA extraction from PBMCs. The RNA concentration and the A260/A280 ratio was 
measured using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA). The integrity of the RNA was assessed using agarose gel electrophoresis. 
Five μg of the total RNA was converted to first strand cDNAs in 100 μL reactions using 
random primers (High-Capacity cDNA Archive Kit P/N 4322171, Applied Biosystems, Foster City, 
CA). 
 
4.2.5.3 Quantitative real time polymerase chain reaction (Studies I and IV) 
Real-time PCR (QPCR) analyses were performed using an ABI Prism 7500 Real-Time PCR system 
and assays based on TaqMan chemistry and ABI Prism 7500 SDS software (Applied Biosystems, 
Foster City, CA) as described earlier (321). The gene expressions investigated are presented in the 
Table 9. The expression of cyclophilin A1 was used as an endogenous control for adipose tissue 
and GAPDH for PBMCs. Each PCR consisted of 6 ng of cDNA, 1 x Assay Mix and 1 x TaqMan 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA) or Absolute QPCR ROX Mix 
(ABgene, Epsom, United Kingdom). The samples were analysed as triplicates. For the standard 
curve, all samples of obese subjects were pooled to generate a representative cDNA for standard 
dilutions using methods described in the ABI Prism User Bulletin # 2. Quantities on each plate 
were first corrected by the calibrator on the plate. Furthermore, the relative amount/plate was 
corrected with the corresponding values of endogenous control and final gene expression levels 
are expressed in arbitrary units (AU). 
 
Table 9. The gene expressions investigated.  
Study  Tissue Gene Gene Symbol
Study I SAT Serum amyloid A SAA 
 SAT Leptin LEP 
 SAT Tumour necrosis factor α TNF- ALPHA 
Study IV SAT, PBMCs Fat mass and obesity associated FTO 
 SAT Tumour necrosis factor α TNF- ALPHA 
 SAT High mobility group box 1 HMGB1 
 SAT Hypoxia-inducible factor 1 a HIF-1a 
SAT=subcutaneous adipose tissue, PBMCs=peripheral mononuclear cells 
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4.2.6 Cell culture experiments (Study IV) 
PoieticsTM Human Subcutaneous Preadipocytes (PT-5020) were purchased from Lonza Group Ltd 
(Switzerland). The cells were thawed, cultured and differentiated according to the manufacturer's 
instructions. Briefly, cells were grown in Preadipocyte Growth Medium-2 containing 10% fetal 
bovine serum (FBS), 2mM L-glutamine and penicillin/streptomycin, 100 units/mL and 100μg/mL, 
respectively in the presence of 5% CO2 at 37°C. To induce adipogenic differentiation, the confluent 
cell layers in 6-well plates were cultured in the presence of basal medium supplemented with 
PGMTM-2 SingleQuots® (FBS, L-glutamine, penicillin/streptomycin, insulin, dexamethasone, 
indomethacin, 3-isobutyl-1-methylxanthine, Lonza Group Ltd). On days 4-5 the lipid vacuoles 
appeared and 7-10 days they increased in size. After day 10 they were fully differentiated. 
The gene expression of FTO was studied in different stages of differentiation at days 0 
(preadipocyte), 2, 4, 8 and 10 days after the initiation of adipogenesis. Moreover, the FTO gene 
expression was studied in mature adipocytes (day 10 postdifferentiation) and after 24-hour 
treatment with TNF-α (20 ng/ml). In the gene expression analyses, cyclophilin A1 was used as an 
endogenous control. 
 
4.2.7 Statistical analyses 
Statistical tests were performed using the SPSS statistical software for Windows (version 14.0, SPSS 
Inc., Chicago, IL). Normal distribution was tested using the Kolmogorov-Smirnov test with 
Lilliefors correction. Logarithmic transformation was used when appropriate. Homogeneity of 
variances was tested using Levene’s test. The Hardy-Weinberg equilibrium (HWE) and genotype 
distribution among study groups were analysed with the χ2-test. Data are given as means ± SD or 
medians (interquartile ranges) and p<0.05 was considered statistically significant. 
For the continuous and normally distributed variables, the comparisons between the groups 
(genotypes, genders or normal vs. obese subjects) were made with the general linear model (GLM) 
univariate analyses with appropriate adjustments. The GLM for repeated measures was used for 
analysing the interaction of time and group (Study I). If the GLM was significant, independent 
samples t-test was used for analysing comparisons between different groups, and paired samples 
t-test was used for comparing the baseline and endpoint variables within the study group.  
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Genetic associations were analysed with additive (all three genotypes) and recessive (minor 
allele homozygotes vs. other genotypes) genetic models (Studies II-IV). Genetic associations with 
continuous variables were analysed with linear mixed models during the 4 years of follow-up 
(Studies II-III). The associations with BMI and weight changes during 1 and 4 years were assessed 
with GLM univariate analyses. The changes were calculated by subtracting the first year and 
averaged annual values during the 4.1-year follow-up from the baseline values, correspondingly. 
Appropriate adjustments were used in the analysis when applicable. Subgroup analyses in the 
gender or intervention group were performed when the genotype x group or genotype x gender -
interaction term was significant in the whole-group analysis. Linear regression analyses were used 
to assess the influence of SNP, BMI and age on the variation of clinical parameters (Study III).   
In the DPS, the association of FTO SNP (rs9939609) with CVD risk was analysed with Cox 
regression model using appropriate covariates. In the METSIM study, the association of the SNP 
with prevalence of myocardial infarction was tested using logistic regression. Data are presented 
as hazard ratios (HR) or odds ratios (OR) with 95% confidence interval (CI). 
The correlations were calculated with the Pearson and Spearman methods (Studies I and IV). 
Partial correlations were calculated to control for confounding factors. Multiple linear regression 
analysis was used to assess the influence of age, percentage of fat, size of adipocyte, leptin mRNA, 
and TNF-α mRNA levels on the variation of SAA mRNA (Study I).  
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5 RESULTS 
 
5.1 Circulating inflammatory markers (Study I) 
During the lifestyle intervention in the GENOBIN study, the 33-week intervention decreased the 
measures of body adiposity and fat distribution (Table 10) (321). Serum concentrations of TNF-α 
and leptin also decreased in the weight reduction group (Table 10). There were no significant 
changes in serum SAA concentration. 
At baseline, the obese subjects (BMI from 28.6 to 42.5 kg/m2) showed increased serum 
concentrations of SAA, leptin, and IL-6, but not of hs-CRP and TNF-α when compared with 
normal weight control subjects (Study I) (Figure 3). In the obese subjects, a significant gender 
difference was found in serum SAA and leptin concentrations. In women, the SAA concentration 
was 35.6±32.0 μg/ml and that of leptin 30.2±9.7 ng/ml, whereas the respective values for men were 
17.7±9.8 μg/ml and 11.7±5.9 ng/ml (p<0.001 for both).  
In the obese subjects, serum SAA concentration correlated positively with BMI (r=0.43, 
p<0.001), body fat mass (r=0.43, p<0.001), hs-CRP concentration (r=0.51, p<0.001) and serum leptin 
concentration (Figure 4A). The latter association remained significant after adjustment for fat mass 
(r=0.24, p=0.039). The concentration of SAA was not associated with the serum concentrations of 
total or HDL cholesterol or apo A-I. 
 
Table 10. Changes in clinical characteristics during the 33-week intervention in weight reduction 
and control groups (Study I). 
 Weight reduction (n=28) Control (n=18) pa 
Body weight (kg) -4.6 (-6.1 to -3.1)b -0.2 (-1.0 to 0.6) 0.0002
BMI (kg/m2) -1.62 (-2.2 to -1.1)b -0.10 (-0.4 to 0.2) 0.0002
Waist circumference (cm) -3.6 (-4.9 to -2.3)b 0.6 (-0.5 to 1.7) 0.0001
Body fat mass (kg) -3.0 (-4.2 to -1.8)b -0.5 (-1.1 to 0.1) 0.009 
Serum SAA (μg/ml) -3.2 (-15.3 to 8.9) 4.0 (-8.4 to 16.4) 0.468 
Serum leptin (ng/ml) -3.2 (-4.9 to -1.4)b -0.5 (-1.8 to 0.8) 0.050 
Serum hs-CRP (mg/l) -0.02 (-2.0 to 1.9) 0.3 (-0.2 to 0.9) 0.623 
Serum IL-6 (pg/ml) -0.2 (-0.7 to 0.2) 0.3 (0.05 to 0.7) 0.079 
Serum TNF-α (pg/ml) -0.6 (-1.2 to -0.03)b -0.6 (-1.4 to 0.2) 0.996 
Data are mean change and 95% confidence interval. 
aGLM univariate corrected with age, gender and weight at baseline 
bp<0.05 in paired samples t-test for the change from baseline to the end of the intervention within the group 
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Figure 3. Concentrations of serum amyloid A (A), interleukin 6 (B), tumour necrosis factor α (C), C-reactive 
protein (D), leptin (E) and adiponectin (F) between obese (n=75) and normal weight subjects (n=10) at 
baseline (Study I). 
 
B 
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51 
 
 
Figure 4. The association of serum amyloid A and leptin concentrations in (A) 75 obese subjects (r=0.52, 
p<0.001), and (B) 11 normal weight control subjects (r=0.83, p=0.002), and the association of serum amyloid A 
and leptin mRNA levels in subcutaneous adipose tissue in (C) 75 obese subjects (r=0.64, p=0.001), and (D) 10 
normal weight control subjects (r=0.80, p=0.006) at baseline. Black circles represent men and white represent 
women (337). 
 
 
5.2 Gene expression studies (Studies I and IV)  
5.2.1 Gene expression of SAA (Study I) 
In subcutaneous adipose tissue, there were no differences in SAA mRNA levels between obese and 
normal weight subjects. However, the expression of SAA was higher in obese women than in obese 
men (Figure 5).  
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Figure 5. Gene expression of serum amyloid A in subcutaneous adipose tissue between women and men 
among obese subjects at baseline (Study I). 
 
In the obese subjects, there was a positive correlation between SAA mRNA levels and fasting 
serum SAA concentration (r=0.37, p=0.001), body fat mass (r=0.29, p=0.015) and adipocyte cell size 
(r=0.31, p=0.008). There was also a positive association between the SAA mRNA and the serum 
leptin concentration (r=0.59, p<0.001), which was independent of fat mass (r=0.60, p<0.001). 
Furthermore, there was a positive association between the mRNA levels of SAA and leptin (Figure 
4C), also when adjusted for body fat (r=0.63, p<0.001). 
In the normal weight control subjects, there were also significant correlations between the 
serum concentrations and mRNA levels of SAA and leptin (Figure 4B and 4D). 
 
During the intervention, the overall difference in the change in SAA mRNA with time was 
significant between the weight reduction and obese control groups (p=0.004). Further analysis 
indicated that the SAA mRNA level increased (p=0.002) in the weight reduction group, in both 
women and men (p=0.035; p=0.030, respectively). 
  
5.2.2 Gene expression of FTO (Study IV) 
The mRNA expression of FTO in subcutaneous adipose tissue was up-regulated in obese subjects 
compared with normal weight subjects (Figure 6). FTO mRNA levels did not correlate with 
adiposity markers such as BMI, waist circumference, fat mass or adipocyte cell size and there were 
no differences in FTO mRNA levels between the FTO rs9939609 genotype groups (105±32 AU for 
TT, 110±33 AU for AT and 106±32 AU for AA genotypes). There was no gender difference in FTO 
mRNA levels either. 
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Figure 6.The gene expression of FTO in subcutaneous adipose tissue in obese (n=115) and normal weight 
subjects (n=10). 
 
In obese subjects, the gene expression of FTO and HMGB1 correlated strongly with each 
other in subcutaneous adipose tissue (r=0.75, p<0.001, adjusted for BMI and adipocyte cell size). 
Moreover, mRNA level of FTO correlated positively with the gene expression of HIF-1a (r=0.61, 
p<0.001, adjusted for BMI and adipocyte cell size). There were no differences in the expression of 
these genes between the FTO genotype groups according to SNP rs9939609.   
FTO mRNA levels in adipose tissue did not correlate with serum concentrations of hs-CRP, 
TNF-α or IL-6 or levels of TNF-α mRNA in subcutaneous adipose tissue. There were no 
correlations between these inflammatory markers and FTO mRNA level in normal weight subjects.   
There was no difference in FTO expression in PBMCs between the 56 obese and 10 normal 
weight subjects (117±32 AU for obese and 135±45 AU for normal weight subjects). The FTO mRNA 
levels in PBMCs did not correlate with adiposity markers or serum concentrations of inflammatory 
markers. 
 
5.3 Association studies (Studies II-IV) 
5.3.1 Genotype frequencies 
The observed genotype frequencies in FTO SNP rs9939609 followed Hardy-Weinberg equilibrium 
in all studies. The minor allele frequency was 0.424 in the DPS, 0.400 in the METSIM and 0.455 in 
the GENOBIN study. 
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5.3.2 FTO, obesity and anthropometric measurements (Study II) 
At baseline the subjects with the rs9939609-AA genotype had a higher BMI (Table 11) than those 
carrying the T allele.  However, there were no significant differences in body weight. In analyses 
stratified by sex, these associations were observed only in women. Individuals with the AA 
genotype also had a larger waist circumference (p=0.025 for the recessive model among all subjects, 
p=0.01 in women) than those with other genotypes, but the effect was abolished when adjusted for 
BMI.   
 
Table 11. Baseline characteristics in the Finnish Diabetes Prevention Study according to the 
genotypes of rs9939609 of the FTO gene.  
rs9939609  TT TA AA p 
additive 
model 
p 
recessive 
model  
Gender 
(male/female) 
 55/113 83/158 27/66 0.705a 0.426a 
Weight (kg) All 85.2 ± 14.4 (167) 86.3 ± 14.2 (240) 87.5 ± 14.3 (92) 0.335b 0.186b 
 Male 89.7 ± 11.1 (55) 92.2 ± 14.4 (83) 91.7 ± 11.0 (27) 0.703c 0.744c 
 Female 83.1 ± 15.3 (113) 83.2 ± 13.1 (158) 85.8 ± 15.2 (66) 0.343c 0.164c 
BMI (kg/m2) All 30.9 ± 4.7 (167) 31.0 ± 4.3 (240) 32.4 ± 4.8 (92) 0.022b 0.006b
 Male 29.4 ± 2.9 (55) 29.9 ± 3.9 (83) 30.6 ± 3.3 (27) 0.325c 0.218c 
 Female 31.7 ± 5.1 (113) 31.6 ± 4.5 (158) 33.1 ± 5.1 (66) 0.056c 0.016c
Data are mean±S.D. 
aχ2-test; bANOVA adjusted for age and sex; cANOVA adjusted for age 
 
During the 4-year follow-up, in all DPS participants, those with the AA genotype 
consistently had a higher BMI than the other genotypes (Figure 7A). The difference was, however, 
statistically significant only in women (Figure 7B and 7C). Due to the significant interactions of 
genotype*randomisation group, the groups were analysed separately and a significant difference 
in BMI was only observed in the control group during the follow-up (Figure 7D and 7E).  
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Figure 7. Body mass index (BMI, kg/m2; mean±S.E.M.) in the entire study population (A) n=502, in men (B) 
n=165, in women (C) n=337, in the intervention group (D) n=255 and in the control group (E) n=247 according 
to the SNP rs9939609 during the 4-year follow-up of the DPS study (338). 
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5.3.3 FTO, lipids and glucose metabolism (Studies II and III) 
In the DPS, there were no clear associations between FTO genotypes/alleles and measures of 
glucose tolerance at baseline. In men only, the variant rs9939609 was associated with the 2h-
plasma glucose, such that carriers of the A-allele had higher concentrations. During the follow-up 
period of 4 years, the sequence variation in the FTO gene was not associated with the incidence of 
T2D (HR 0.922, p=0.738 for recessive model adjusted for BMI and study group). 
In men, the variant rs9939609 was associated with serum HDL cholesterol concentration, 
such that carriers of the AA genotype had lower concentrations than those with the other 
genotypes (Table 12). Additional adjustment for smoking status, use of cholesterol-lowering 
medication, alcohol consumption, and baseline leisure-time physical activity did not change the 
results. The association with HDL cholesterol concentration remained significant in men during 
the 4-year follow-up (p=0.019 in the recessive model adjusted for age, BMI and study group). There 
were no associations between the variant rs9939609 and the concentrations of serum triglycerides 
or total or LDL cholesterol (Table 12). 
 
5.3.4 FTO and inflammatory markers (Studies III and IV) 
In the DPS, the variant rs9939609 was associated with serum concentration of hs-CRP in men so 
that individuals with the AA-genotype had higher concentrations than those with other genotypes 
(2.36 ± 4.31 vs. 4.07 ± 7.13 mg/l, p=0.036 in the recessive model). However, this association was 
abolished after additional adjustment for BMI (Table 12). Interestingly, the A-allele was also 
associated with higher serum levels of RANTES in men, and the association remained significant 
after an adjustment for BMI (Table 12). In men, each copy of the rs9939609-A-allele increased the 
serum concentration by 19.2 pg/ml (p=0.004). 
In Study IV, the carriers of the AA genotype tended to have higher serum concentrations of 
hs-CRP, IL-6 and TNF-α for both genders, but these findings did not reach statistical significance. 
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5.3.5 FTO and cardiovascular diseases 
In the DPS, the rs9939609-AA genotype was associated with increased incidence of CVD (HR=2.09, 
95% CI 1.17-3.73, p=0.013 in the recessive model, adjusted for baseline BMI, age, sex, group, systolic 
blood pressure, serum total cholesterol, hs-CRP, use of antihypertensive drugs, use of 
statin/fibrate, smoking status and baseline CVD, Table 13). Due to the significant genotype x 
gender -interaction, men and women were also analysed separately. Thereafter, the association 
with the incidence of CVD was evident only in men (Figure 8A). In the recessive model adjusted 
for baseline BMI, age, use of antihypertensives, use of statin/fibrate and baseline CVD, men with 
the AA genotype had approximately two times higher risk for developing CVD than men with the 
other genotypes (HR= 2.14, 95% CI 1.10-4.17, p=0.025 in the recessive model). Additional 
adjustment for HDL cholesterol concentration did not change the results (HR=2.04, 95% CI 1.05-
3.95, p=0.035). Even further adjustments for RANTES concentration and smoking status did not 
decrease the risk considerably although the significance attenuated to a nonsignificant level 
(HR=1.86, 95% CI 0.76-4.56, p=0.174). In the METSIM study, the association with the CVD was 
replicated in the subgroup of subjects with type 2 diabetes (Figure 8B) (OR=1.74 for the association 
with a history of myocardial infarction, 95% CI 1.03-2.94, p=0.037, adjusted for age and BMI in the 
recessive model). 
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A) 
B) 
 
     
 
 
 
 
 
 
 
Figure 8. 
A) Survival curves of the incidence of CVD 
in men of the Finnish Diabetes Prevention 
Study according to genotype in the recessive 
genetic model (minor allele homozygotes vs. 
other genotypes) adjusted for baseline BMI, 
age, use of antihypertensives, use of 
statin/fibrate and CVD; OR=2.14, 95% CI, 
1.10-4.17, p=0.025. 
 
B) Odds ratios for the cross-sectional 
association of the FTO gene variant 
rs9939609 with a history of myocardial 
infarction in the METSIM by subgroups of 
subjects having normal glucose tolerance 
(NGT) [OR (95% CI): 0.75 (0.46-1.23), 
p=0.248], impaired fasting glucose 
(IFG)/impaired glucose tolerance (IGT) [1.09 
(0.63-1.89), p=0.756], or type 2 diabetes 
(T2DM) [1.74 (1.03-2.94), p=0.037]. Recessive 
model, adjusted for BMI and age. 
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6 DISCUSSION 
 
6.1 Methodological considerations 
6.1.1 Study populations 
All study populations consisted of Finnish subjects. The Finnish population is unique among 
the Caucasian populations due to its genetic homogeneity (339). Furthermore, considerable 
environmental and cultural similarities reduce the confounding factors that hamper genetic 
studies in more mixed populations. However, quite recently Salmela et al. (340) suggested 
that attention to population substructure may be needed to ensure the quality of association 
studies performed in Finnish samples.  
The Finnish DPS participants in the Studies II and III were overweight or obese and 
had IGT at baseline (252). Thus, they were representative for individuals of developing type 
2 diabetes and formed an important high risk group for actions aimed at preventing the 
disease. Furthermore, individuals with abnormal glucose metabolism are at increased risk 
for CVD (341). Components of the insulin resistance have also been related to inflammatory 
markers (342,343). DPS participants therefore represented individuals having chronic 
subclinical inflammation (289,344). 
For genetic association studies, the DPS population might be considered too small. 
However, the strength of the DPS cohort is that individuals are carefully selected and 
clinically well characterized. They also form a homogenous group with long-term follow-up 
data. Thus, it is a unique study to explore gene x environment interactions. 
The METSIM study (Study III) was a population-based cross-sectional sample of 6214 
men (327,328) which provided large cohort with sufficient statistical power.  Drawbacks of 
the METSIM study are that it currently provides only cross-sectional data on men.  
The participants in the GENOBIN and FUNGENUT studies (Studies I and IV) had 
features of metabolic syndrome and IGT and/or IFG and formed a homogenous study 
population similarly to the DPS population.  The major limitations in these studies were the 
small sample sizes, especially for genetic associations. However, these studies were 
originally clinical interventions, and the methods employed (e.g. adipose tissue biopsies) 
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were complex, time-consuming and expensive, and therefore difficult to apply to a much 
larger group of participants. 
 
6.1.2 Genetics and gene expression 
In Studies II-IV, variant rs9939609 in the first intron of FTO, was selected because it was 
reported with the highest genotyping success rate in a cluster of SNPs highly associated 
with obesity (43). There is a possibility that this SNP is in linkage disequilibrium with the 
true functional variant(s) within the FTO gene or nearby genetic regions (45). However, in 
contrast to GWA studies, candidate gene studies limit the number of tests to a small subset 
of the genome. 
Genotyping were performed with the customised GoldenGate and TaqMan assays. 
Both methods are accurate, robust and widely used.  The likelihood for technical errors is 
low, because genotyping was repeated in a representative sample to confirm the accuracy. 
Furthermore, a test for Hardy-Weinberg equilibrium was performed for each study. There 
were no significant deviations, which diminishes the risk for genotyping errors (345,346).  
The TaqMan RT-qPCR technique was used for gene expressions, which enables the 
measurement of an accumulating PCR product in real time by using a dual-labelled TaqMan 
fluorogenic probe (347). Due to the extremely high specificity of TaqMan primer and probe 
sets, this technique is relatively quick and widely used in hypothesis-driven identification of 
candidate genes. Primers and probes for simultaneous detection of SAA1 and SAA2 
isoforms were designed using the region between exon 3 and 4 which reduces the risk of 
DNA contamination. Primers and probes for all other markers were purchased as pre-
designed assays.  
The standards used in gene expression analyses were made as separate pools for obese 
and normal weight study subjects. A good standard should not be different between groups 
of subjects and if there are differences, one can make a global pool of these two pools. 
Unfortunately, in normal weight subjects the adipose tissue sample volumes were smaller 
and thus RNA yield clearly lower than in obese subjects. To accomplish individual gene 
expression analyses, we were not able to mix these two groups to make a global pool and 
common standard curve. However, this procedure made possible to perform numerous 
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experiments with the same standard dilutions for each group, which reduced interassay 
variation.  
It is also of importance to note that the gene expression analyses were performed only 
on subcutaneous adipose tissue samples. Visceral adipose tissue is also an active fat depot, 
which has a unique inflammatory profile compared with subcutaneous fat (348). However, 
visceral samples are usually obtained during surgical operations from morbidly obese 
subjects. Therefore, in Studies I and IV these samples were not considered.  
 
6.1.3 Statistical issues 
It could be argued that since the associations with FTO SNP rs9939609 and different 
phenotypes were analysed in Studies II-IV, the levels of significance should be corrected for 
multiple comparisons. The simplest and most straightforward correction for multiple testing 
is the Bonferroni adjustment, in which nominal p-values are multiplied by the total number 
of tests performed. The underlying assumption is that the set of tests are independent. 
Therefore, the Bonferroni correction is considered overly conservative in the context of 
correlated tests (349). Accordingly, testing closely correlated phenotypes (such as waist 
circumference and BMI) should not require as much of a p-value correction as would testing 
completely uncorrelated phenotypes (350). In Studies II-IV, we tested associations of a single 
marker and thus, we did not correct for multiple testing.  
The sample sizes in the DPS and especially in the Study IV were modest for genetic 
association studies. It should be noted these studies were not originally designed for genetic 
association studies such as those performed at present. Furthermore, the feasibility of 
retrospective calculations of statistical power is questionable (351). We cannot rule out the 
possibility that the lack of statistically significant results might have been due to inadequate 
sample size. Thus, in the future, larger studies with more statistical power are needed. 
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6.2 General discussion 
 
6.2.1 Serum amyloid A and low-grade inflammation 
In Study I, SAA, IL-6 and leptin concentrations were increased in abdominally obese men 
and women with the metabolic syndrome compared with normal weight subjects. Our 
observation is in line with the presence of a low-grade inflammatory state, a hallmark 
characterising obesity. The novel findings of Study I were that serum concentrations and 
gene expressions of leptin and SAA were associated with each other in both obese and 
normal weight subjects. However, the mechanism linking leptin and SAA is not yet clear. 
SAA production is induced by the pro-inflammatory cytokines, TNF-α and IL-6 (352). Since 
leptin induces both TNF-α and IL-6 production, it is conceivable that SAA production is up-
regulated by leptin via these cytokines (353). However, the cross-sectional association of 
SAA and leptin does not permit conclusions on the directionality, and further studies are 
needed to elucidate the mechanism. 
If leptin induces SAA production, it may provide a novel mechanistic link between 
obesity and the associated vascular complications. SAA is a significant predictor of coronary 
artery disease risk in women, but the mechanism of the association is not understood (86-
88). Secondly, there is also increasing evidence of an association between leptin and 
cardiovascular risk (354,355). In obesity, both leptin and SAA are increased simultaneously, 
which may even further increase cardiovascular risk. 
 
In Study I, the 33-week intervention with a weight loss at least 5% increased mRNA 
expression of SAA in subcutaneous adipose tissue, even though the respective serum 
concentration was unchanged. This observation is in contrast to previous findings (75,78,81). 
Discrepancies between these outcomes can be due to differences in study designs. The 
subjects in the prior studies have been severely obese and underwent a very-low-calorie diet 
or a bariatric surgery, resulting in a drastic short-term weight loss. In the Study I, however, 
the subjects were less obese, and the weight loss was modest. Furthermore, it may be that 
the 5-month follow-up period allows compensatory mechanisms to be up-regulated. Our 
aim was to examine the effects of a long-term non-surgical weight reduction program, which 
is more relevant in every day clinical practice.  
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It should also be taken into account that concomitant gene expression changes in 
visceral adipose tissue remain unknown. Previously it has been shown that SAA is highly 
expressed also in omental adipose tissue (78).  
 
6.2.2 FTO and obesity  
The FTO gene is currently the most consistently replicated gene for obesity in humans. The 
first studies establishing this association were published in 2007 (43-45). Since then, multiple 
studies have confirmed the association. In Study II, our results likewise confirm the 
association between the common FTO variant rs9939609 and BMI in a cross-sectional setting 
and also during the long-term lifestyle intervention study. 
In analyses stratified by gender, the association between FTO and BMI was observed 
only in women. The absolute differences in BMI by the FTO genotype were small, however, 
and the trend was in the same direction in both genders. Jacobsson et al. (96) have reported a 
similar gender effect in children. They showed that among obese children, girls with the AA 
genotype were more obese than those with other genotypes. Such a difference by FTO 
genotype was not observed among obese boys. The effect of FTO on body weight may 
therefore depend on gender.  
 
6.2.3 FTO and obesity-induced risk factors 
In the DPS, FTO variant rs9939609 was associated with RANTES and hs-CRP concentrations 
in men. The association with RANTES concentration was independent of BMI. The 
association with hs-CRP was abolished after adjustment for BMI, however, which is in 
contrast to observation by Fisher et al. (106). Discrepancies between these outcomes may be 
due to the differences in study populations. Fisher et al. (106) examined the association in a 
population-based sample, whereas all DPS study participants had IGT at baseline. In Study 
IV, we found a trend for the BMI-independent association between FTO variation and 
inflammatory markers (hs-CRP, TNF-α and IL-6). Based on these findings, we speculate that 
the variation in FTO gene may contribute to the variability of inflammatory markers in 
serum. In accordance with this hypothesis, a recent study showed associations between FTO 
mRNA level and expressions of the TNF-α and NF-κB (154), which supports the role of FTO 
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in modulating inflammation. However, in our cell culture experiments with a human cell 
line, we were not able to detect any effects of the TNF-α treatment on FTO mRNA levels in 
mature adipocytes. In macrophages, the FTO expression has been shown to be drastically 
upregulated when treated with inflammatory stimulants (144). Thus, Qi et al. (144) have 
speculated that FTO is a possible molecular link between metabolism and inflammation in 
the pathogenesis of obesity-related metabolic diseases.   
In the DPS, we found an association between the FTO variant and decreased HDL 
cholesterol level, which is in accordance with three recent reports (105,127,128). However, 
we detected the association only in men, and moreover, the association was independent of 
BMI. These findings provide further evidence that the FTO genotype may have a BMI-
independent metabolic effect. In contrast to some previous findings, we did not find 
significant associations between the A allele and higher triglyceride levels (128,150).  
 
6.2.4 FTO and cardiovascular diseases 
In Study III, we demonstrated that the AA genotype of the FTO rs9939609 variant was 
associated with increased CVD risk in men with either IGT or type 2 diabetes and the 
association was not explained by the conventional CVD risk factors. Our findings are in 
accordance with recent findings (127,356,357). We suggest that the effect of rs9939609 on 
CVD risk may be modulated by glucose metabolism. Both IGT and type 2 diabetes increase 
the risk of CVD independently of other known risk factors (193-195). The METSIM study 
provided further credibility for our hypothesis, since the interaction between the variant 
rs9939609 and glucose tolerance status with respect to a history of myocardial infarction was 
highly significant.  
Hubacek et al. (356) have proposed that FTO variants could enhance the risk of acute 
coronary syndrome through another mechanism, namely through its possible effect on DNA 
methylation (i.e. the epigenetic status). FTO has been described as an apparently Fe(II)- and 
2-oxoglutarate-dependent oxygenase that might operate as a DNA demethylase (145). Thus, 
this hypothesis could present a link between FTO and CVD. However, there are no data 
available yet about the total DNA methylation status and FTO genotype. 
In the DPS, the inflammatory markers or decreased HDL cholesterol concentration do 
not seem to explain the association between FTO and CVD either. Although the association 
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of the FTO A allele with increased CVD risk was weakened when adjusted for RANTES 
concentrations, the hazard ratio remained almost the same. Thus, we suggest that increased 
RANTES levels may explain part of the observed CVD risk with the A allele, but it most 
likely is not the only factor. Increased RANTES concentrations in men compared to women 
might be one factor explaining the gender difference of the CVD risk in the DPS, but the 
main reason for the gender difference is currently unknown. 
Further evidence is nonetheless needed to confirm whether the FTO SNP is an 
independent predictor for CVD and whether an abnormal glucose metabolism has a role in 
this association. It should be noted that the vast majority of CVD risk is under polygenic 
control. Although many candidate genes for CVD have been established, the association 
with the FTO gene variant rs9939609 has been confirmed only in a few studies before 
(127,356,357). 
 
6.2.5 FTO and the effect of lifestyle changes  
Evidence concerning the potential modifying effect of the FTO gene on body weight 
changes achieved by lifestyle changes is still quite limited. In our study (Study II), the FTO 
variant rs9939609 did not modify weight reduction achieved by a lifestyle intervention 
modifying diet and physical activity. Previous reports have been inconclusive (104,309). It 
should be noted that the association of rs9939609 genotype with weight change remained 
non-significant after adjusting for baseline BMI. The weight development was also similar 
among all FTO genotypes in the control group: the individuals with the AA genotype had a 
higher BMI during the entire study period. Thus, it is unlikely that the variants of the FTO 
gene substantially modify the effect of lifestyle modification on the success of weight 
reduction in the long- term. 
One could expect less weight loss in carriers of the A allele. It may be that the 
intervention must be sufficiently long to observe the modifying effects of the FTO genotype. 
In the DPS, however, the most intensive intervention period was long-term and the changes 
in clinical characteristics were prominent (358).  
It has been reported that sedentary lifestyle may accentuate the effects of the genetic 
variation in the FTO gene on body fat accumulation and the increased risk of obesity can be 
blunted through physical activity (Table 7). In our study, the genotype of rs9939609 was not 
68 
 
associated with physical activity level. Moreover, the changes in physical activity during the 
follow-up period did not modify the genetic associations with body weight. This is in 
accordance with a study on men in which physical activity had no influence on the 
association between rs9939609 genotype and fat mass (171). In the DPS, it should be noted, 
that the lifestyle intervention was not focused solely on physical activity. Instead, three out 
of the five main goals focused on diet, and physical activity was only one of the five goals 
(252).  
Because of the multi-factorial nature of obesity, each individual genetic variant 
generally has only a modest effect, and the interaction of genetic variants with each other or 
with environmental factors can potentially be quite important in determining the observed 
phenotype.  Accordingly, Reinehr et al. (311) analysed the effect of two different SNPs 
(insulin induced gene 2, INSIG2: rs7566605 and FTO: rs9939609) on weight change in a 1-
year lifestyle intervention program in children. They demonstrated that the homozygote 
combination of INSIG2 and FTO risk alleles was significantly associated with the lowest 
degree of overweight reduction, providing evidence towards gene-gene interactions for 
weight loss during a long-term lifestyle intervention. Furthermore, Cauchi et al. (314) 
showed in European general populations that the combined effects of common 
polymorphisms in FTO and melanocortin-4 receptor gene (MC4R) are additive and 
predictive of obesity. In the future, it will also be of importance to investigate gene-gene 
interactions in our study settings. 
 
6.2.6 Gene expression of FTO 
The strong association of genetic variation within FTO with obesity has led to a series of 
functional studies including gene expression analyses. However, little is yet known about 
the functions of FTO and biological significance of various associations.  The human FTO is 
widely expressed in various tissues, including adipose tissue, pancreas, liver, placenta and 
the especially the brain, specifically in the hypothalamus (98,143,144,149,359).  
In Study IV, we detected higher expression levels of FTO in subcutaneous adipose 
tissue in obese than in the group of normal weight subjects. This finding is in accordance 
with previous studies and accentuates the role of FTO in adipocyte function (143,150,151). 
Contrary to previous findings (143), the expression of FTO was increased during the 
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adipogenesis, indicating that it may have a role in the differentiation of adipocytes. The 
reason for the opposite findings may be the differences in the cell culture procedures. The 
FTO expression in adipose tissue was not influenced by FTO variation, which is in line with 
previous findings (143,149).  
In Study IV, we demonstrated FTO mRNA to be expressed in PBMCs. Previously in 
humans, FTO mRNA levels has been detected in leukocytes, and more specifically in 
lymphocytes (144,360). Whether FTO expression in immune cells has a role in inflammatory 
processes remains to be elucidated. 
 
In the gene expression analyses (Study IV), FTO mRNA level correlated strongly with 
HMGB1 and HIF-1a in subcutaneous adipose tissue. Although the causality of these 
associations is unclear, they suggest a mechanism by which FTO may influence fat mass. 
Interestingly, at the time when FTO was identified, the locus was hypothesised as a 
candidate for programmed cell death (94,95). Furthermore, Klöting et al. (152) have 
suggested that FTO gene expression might be down-regulated in response to fat 
accumulation. This hypothesis is in line with the fact that the rate of adipocyte death is 
elevated in obesity (61,62), partly due to hypoxia (361). TNF-α is also an important regulator 
of fat cell function to limit adipose tissue expansion (362). However, we could not detect a 
difference between the FTO genotypes and the expression of TNF-α in subcutaneous adipose 
tissue. 
Since the FTO SNPs do not correlate with FTO mRNA expression across multiple 
tissues, it is plausible that other genes may participate in mediating these effects and that 
downstream processes may have the potential to affect FTO gene expression indirectly (363). 
FTO variant(s) may also be associated with obesity through an effect on other genes, such as 
retinitis pigmentosa GTPase regulator-interacting protein 1-like (RPGRIP1L) or 
retinoblastoma-like 2 (RBL2). The transcription start site of the RPGRIP1L gene is in close 
proximity (400 bp) to the 5’ end of FTO (43) and RBL2 is located 270 kb upstream of FTO. 
Furthermore, the presence of multiple, associated non-coding intragenic SNPs in high 
linkage disequilibrium make it difficult to distinguish the true causal variant(s). 
Nonetheless, more efforts to determine the actual causative variant(s) are needed.  
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6.3 Concluding remarks and future perspectives 
Over the last decades, the prevalence of overweight and obesity has increased rapidly and 
burdens health care systems worldwide. The etiology of obesity is complex and is based on 
both environmental and multiple genetic factors. 
Advances in adipose tissue biology have led to an improved understanding of the 
mechanisms linking obesity to its numerous systemic complications. Obesity is characterised 
by a chronic, systemic low-grade state of inflammation. Accordingly, we demonstrated in 
Study I increased concentrations of SAA, TNF-α and hs-CRP in obesity. Furthermore, 
correlations between SAA and leptin were detected both in serum and at gene expression 
level.  This may provide a novel mechanistic link between obesity and particularly the 
associated vascular complications. In the future, improved understanding of the role of 
adipose tissue in the activation of inflammatory pathways may provide novel treatment and 
prevention strategies aimed at reducing obesity and co-morbidities. 
Several studies suggest that weight loss is associated among other clinical benefits 
with an improved systemic inflammatory state (Table 2). The greatest improvements in the 
inflammatory profiles are noted in those achieving drastic weight loss e.g. due to gastric 
surgery. In Study I, the 33-week modest weight loss including weight maintenance period 
increased mRNA expression of SAA in subcutaneous adipose tissue even serum SAA 
concentration remained unchanged. Further studies are needed to determine the time 
required to benefit from improved inflammatory status in the long term. 
 
While it is clear that environmental factors play an important role in the development 
of obesity, research has also clearly documented a genetic contribution to obesity-related 
phenotypes and FTO is the first locus unequivocally associated with obesity.  
With more than one billion overweight and 300 million obese persons worldwide, it is 
crucial to understand the implications of carrying this common allele for the health. 
Furthermore, it is important to identify "intervention-responsive" individuals. Study II was 
one of the first attempts in relation to FTO variant rs9939609 and is therefore of interest. Our 
findings suggested that also the individuals with a genetic predisposition to obesity benefit 
from lifestyle modification and lifestyle changes remain effective way to lose weight.  
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In Study III, we found BMI-independent associations with hs-CRP concentration and 
increased CVD risk. An examination of the effects of FTO variation on quantitative traits 
may improve our understanding of how genetic alteration of FTO to fat mass could 
predispose to obesity-related diseases. It remains to be clarified whether FTO variant results 
in altered fat mass and altered metabolic traits through separate mechanisms. 
Current evidence suggests that FTO could contribute to the risk of obesity via multiple 
central to peripheral processes. In Study IV, we demonstrated FTO expression in 
subcutaneous adipose tissue and in PBMCs. We showed that FTO expression was higher in 
subcutaneous adipose tissue of obese subjects than in normal weight subjects. Furthermore, 
FTO mRNA correlated positively with gene expression levels of HIF-1a and HMGB1. 
Although the causality of these associations remains unclear, they suggest a mechanism by 
which FTO may influence fat mass.  
In the future, identifying the molecular functions and signaling pathways of FTO is 
needed. However, loss of FTO activity leads to severe developmental defects, which 
probably limits therapeutic approach of targeting FTO in pharmacologic obesity treatment. 
Research including epigenetics, will as well improve the knowledge of the still unclear 
functions of the FTO. 
 
Taken together, the discovery of FTO gene has generated many questions to be 
answered. Recently, additional GWA studies have succeeded in identifying many additional 
novel obesity loci (99, 364-366). It is also now evident that in obesity adipose tissue is an 
active participant in the generation of a chronic inflammatory state, which contributes to the 
development of complications of obesity, including type 2 diabetes and CVD. However, 
before all these findings can be converted into clinical benefits, it is necessary to determine 
the precise biological mechanisms by which confirmed obesity susceptibility variants affect 
adiposity and by which inflammatory factors are up-regulated in adipose tissue. A future 
goal would also be to identify the very early signals of inflammation in adipose tissue in 
order to control the interaction between adipocytes and other tissues. Translating new 
advances into useful guidelines for prevention and treatment will be the most demanding 
part.  
 
72 
 
REFERENCES  
 
(1) World Health Organization W. Obesity: Preventing and Managing the Global Epidemic. 
WHO Technical Report Series 894. 894th ed. Geneva, Switzerland: WHO; 2000. 
 
(2) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and 
Obesity in Adults--The Evidence Report. National Institutes of Health. Obes.Res. 1998 Sep;6 
Suppl 2:51S-209S. 
 
(3) Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL, et al. 
Comparisons of percentage body fat, body mass index, waist circumference, and waist-
stature ratio in adults. Am.J.Clin.Nutr. 2009 Feb;89(2):500-508. 
 
(4) Steinberger J, Jacobs DR, Raatz S, Moran A, Hong CP, Sinaiko AR. Comparison of body 
fatness measurements by BMI and skinfolds vs dual energy X-ray absorptiometry and their 
relation to cardiovascular risk factors in adolescents. Int.J.Obes.(Lond) 2005 Nov;29(11):1346-
1352. 
 
(5) Bosy-Westphal A, Geisler C, Onur S, Korth O, Selberg O, Schrezenmeir J, et al. Value of 
body fat mass vs anthropometric obesity indices in the assessment of metabolic risk factors. 
Int.J.Obes.(Lond) 2006 Mar;30(3):475-483. 
 
(6) Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW, et al. Waist 
circumference, waist-hip ratio and body mass index and their correlation with 
cardiovascular disease risk factors in Australian adults. J.Intern.Med. 2003 Dec;254(6):555-
563. 
 
(7) Vazquez G, Duval S, Jacobs DR,Jr, Silventoinen K. Comparison of body mass index, waist 
circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. 
Epidemiol.Rev. 2007;29:115-128. 
 
(8) Gray DS, Fujioka K. Use of relative weight and Body Mass Index for the determination of 
adiposity. J.Clin.Epidemiol. 1991;44(6):545-550. 
 
(9) Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist 
circumference and abdominal sagittal diameter: best simple anthropometric indexes of 
abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and 
women. Am.J.Cardiol. 1994 Mar 1;73(7):460-468. 
 
(10) Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index 
explains obesity-related health risk. Am.J.Clin.Nutr. 2004 Mar;79(3):379-384. 
 
(11) Ellis KJ. Human body composition: in vivo methods. Physiol.Rev. 2000 Apr;80(2):649- 
680. 
 
73 
 
(12) Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among 
US adults, 1999-2008. JAMA 2010 Jan 20;303(3):235-241. 
 
(13) Rissanen A, Heliövaara M, Aromaa A. Overweight and anthropometric changes in 
adulthood: a prospective study of 17,000 Finns. Int.J.Obes. 1988;12(5):391-401. 
 
(14) Lahti-Koski M, Seppänen-Nuijten E, Männisto S, Härkänen T, Rissanen H, Knekt P, et 
al. Twenty-year changes in the prevalence of obesity among Finnish adults. Obes.Rev. 2009 
Oct 27. 
 
(15) Helakorpi S, Paavola M, Prättälä R, Uutela A. Health Behaviour and Health among the 
Finnish Adult Population. 2009;B1. 
 
(16) Kopelman P. Health risks associated with overweight and obesity. Obes.Rev. 2007 Mar;8 
Suppl 1:13-17. 
 
(17) Aromaa A, Heliövaara M, Impivaara O, Knekt P, Maatela J. The Execution of the Mini-
Finland Health Survey. Part 1: Aims, Methods and Study Population. Publications of the 
Social Insurance Institution ML 88: Helsinki and Turku. 1989. 
 
(18) Aromaa A, Koskinen S. Health and Functional Capacity in Finland: Baseline Results for 
the Health 2000 Health Examination Survey. Publications of the National Public Health 
Institute B12/2004: Helsinki, 2004. . 
 
(19) Peltonen M, Harald K, Männistö S, Saarikoski L, Peltomäki P, Lund L, et al. The 
National FINRISK 2007 Study. Publications of the National Public Health Institute. 2008;B34. 
 
(20) Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go 
from here? Science 2003 Feb 7;299(5608):853-855. 
 
(21) Heitmann BL, Lissner L. Dietary underreporting by obese individuals--is it specific or 
non-specific? BMJ 1995 Oct 14;311(7011):986-989. 
 
(22) Nielsen SJ, Siega-Riz AM, Popkin BM. Trends in energy intake in U.S. between 1977 and 
1996: similar shifts seen across age groups. Obes.Res. 2002 May;10(5):370-378. 
 
(23) Swinburn B, Sacks G, Ravussin E. Increased food energy supply is more than sufficient 
to explain the US epidemic of obesity. Am.J.Clin.Nutr. 2009 Dec;90(6):1453-1456. 
 
(24) Silventoinen K, Sans S, Tolonen H, Monterde D, Kuulasmaa K, Kesteloot H, et al. Trends 
in obesity and energy supply in the WHO MONICA Project. Int.J.Obes.Relat.Metab.Disord. 
2004 May;28(5):710-718. 
 
(25) Hill JO. Understanding and addressing the epidemic of obesity: an energy balance 
perspective. Endocr.Rev. 2006 Dec;27(7):750-761. 
 
74 
 
(26) Jeffery RW, Utter J. The changing environment and population obesity in the United 
States. Obes.Res. 2003 Oct;11 Suppl:12S-22S. 
 
(27) Eaton SB, Konner M, Shostak M. Stone agers in the fast lane: chronic degenerative 
diseases in evolutionary perspective. Am.J.Med. 1988 Apr;84(4):739-749. 
 
(28) Li S, Loos RJ. Progress in the genetics of common obesity: size matters. 
Curr.Opin.Lipidol. 2008 Apr;19(2):113-121. 
 
(29) Loos RJ. Recent progress in the genetics of common obesity. Br.J.Clin.Pharmacol. 2009 
Dec;68(6):811-829. 
 
(30) Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K. The 
heritability of body mass index among an international sample of monozygotic twins reared 
apart. Int.J.Obes.Relat.Metab.Disord. 1996 Jun;20(6):501-506. 
 
(31) Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body 
weight and human adiposity. Behav.Genet. 1997 Jul;27(4):325-351. 
 
(32) Nelson TL, Vogler GP, Pedersen NL, Hong Y, Miles TP. Genetic and environmental 
influences on body fat distribution, fasting insulin levels and CVD: are the influences 
shared? Twin Res. 2000 Mar;3(1):43-50. 
 
(33) Boutin P, Dina C, Vasseur F, Dubois S, Corset L, Seron K, et al. GAD2 on chromosome 
10p12 is a candidate gene for human obesity. PLoS Biol. 2003 Dec;1(3):E68. 
 
(34) Meyre D, Boutin P, Tounian A, Deweirder M, Aout M, Jouret B, et al. Is glutamate 
decarboxylase 2 (GAD2) a genetic link between low birth weight and subsequent 
development of obesity in children? J.Clin.Endocrinol.Metab. 2005 Apr;90(4):2384-2390. 
 
(35) Swarbrick MM, Waldenmaier B, Pennacchio LA, Lind DL, Cavazos MM, Geller F, et al. 
Lack of support for the association between GAD2 polymorphisms and severe human 
obesity. PLoS Biol. 2005 Sep;3(9):e315. 
 
(36) Groves CJ, Zeggini E, Walker M, Hitman GA, Levy JC, O'Rahilly S, et al. Significant 
linkage of BMI to chromosome 10p in the U.K. population and evaluation of GAD2 as a 
positional candidate. Diabetes 2006 Jun;55(6):1884-1889. 
 
(37) Weedon MN, Shields B, Hitman G, Walker M, McCarthy MI, Hattersley AT, et al. No 
evidence of association of ENPP1 variants with type 2 diabetes or obesity in a study of 8,089 
U.K. Caucasians. Diabetes 2006 Nov;55(11):3175-3179. 
 
(38) Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T, et al. A common 
genetic variant is associated with adult and childhood obesity. Science 2006 Apr 
14;312(5771):279-283. 
75 
 
(39) Loos RJ, Barroso I, O'rahilly S, Wareham NJ. Comment on "A common genetic variant is 
associated with adult and childhood obesity". Science 2007 Jan 12;315(5809):187; author reply 
187. 
 
(40) Rosskopf D, Bornhorst A, Rimmbach C, Schwahn C, Kayser A, Kruger A, et al. 
Comment on "A common genetic variant is associated with adult and childhood obesity". 
Science 2007 Jan 12;315(5809):187; author reply 187. 
 
(41) Dina C, Meyre D, Samson C, Tichet J, Marre M, Jouret B, et al. Comment on "A common 
genetic variant is associated with adult and childhood obesity". Science 2007 Jan 
12;315(5809):187; author reply 187. 
 
(42) Risch N, Merikangas K. The future of genetic studies of complex human diseases. 
Science 1996 Sep 13;273(5281):1516-1517. 
 
(43) Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A 
common variant in the FTO gene is associated with body mass index and predisposes to 
childhood and adult obesity. Science 2007 May 11;316(5826):889-894. 
 
(44) Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, et al. Variation in FTO 
contributes to childhood obesity and severe adult obesity. Nat.Genet. 2007 Jun;39(6):724-726. 
 
(45) Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, et al. Genome-wide association 
scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS 
Genet. 2007 Jul;3(7):e115. 
 
(46) Faust IM, Johnson PR, Stern JS, Hirsch J. Diet-induced adipocyte number increase in 
adult rats: a new model of obesity. Am.J.Physiol. 1978 Sep;235(3):E279-86. 
 
(47) Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, et al. 
Dynamics of fat cell turnover in humans. Nature 2008 Jun 5;453(7196):783-787. 
 
(48) Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. 
Best Pract.Res.Clin.Endocrinol.Metab. 2005 Dec;19(4):547-566. 
 
(49) MacDougald OA, Burant CF. The rapidly expanding family of adipokines. Cell.Metab. 
2007 Sep;6(3):159-161. 
 
(50) Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of 
the mouse obese gene and its human homologue. Nature 1994 Dec 1;372(6505):425-432. 
 
(51) Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis 
factor-alpha: direct role in obesity-linked insulin resistance. Science 1993 Jan 1;259(5091):87-
91. 
(52) Cancello R, Clement K. Is obesity an inflammatory illness? Role of low-grade 
inflammation and macrophage infiltration in human white adipose tissue. BJOG 2006 Aug 
10. 
76 
 
 
(53) Sethi JK, Vidal-Puig AJ. Thematic review series: adipocyte biology. Adipose tissue 
function and plasticity orchestrate nutritional adaptation. J.Lipid Res. 2007 Jun;48(6):1253-
1262. 
 
(54) Luster AD. Chemokines--chemotactic cytokines that mediate inflammation. 
N.Engl.J.Med. 1998 Feb 12;338(7):436-445. 
 
(55) Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW,Jr. Obesity is 
associated with macrophage accumulation in adipose tissue. J.Clin.Invest. 2003 
Dec;112(12):1796-1808. 
 
(56) Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of 
adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and 
subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004 
May;145(5):2273-2282. 
 
(57) Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J.Clin.Endocrinol.Metab. 
2004 Jun;89(6):2548-2556. 
 
(58) Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin 
concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005 
Oct;54(10):2911-2916. 
 
(59) Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, et al. Depot-related 
gene expression in human subcutaneous and omental adipocytes. Diabetes 1998 
Sep;47(9):1384-1391. 
 
(60) Tchkonia T, Giorgadze N, Pirtskhalava T, Thomou T, DePonte M, Koo A, et al. Fat 
depot-specific characteristics are retained in strains derived from single human 
preadipocytes. Diabetes 2006 Sep;55(9):2571-2578. 
 
(61) Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death 
defines macrophage localization and function in adipose tissue of obese mice and humans. 
J.Lipid Res. 2005 Nov;46(11):2347-2355. 
 
(62) Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW,2nd, DeFuria J, Jick Z, et al. Adipocyte 
death, adipose tissue remodeling, and obesity complications. Diabetes 2007 Dec;56(12):2910-
2918. 
 
(63) Pang C, Gao Z, Yin J, Zhang J, Jia W, Ye J. Macrophage infiltration into adipose tissue 
may promote angiogenesis for adipose tissue remodeling in obesity. 
Am.J.Physiol.Endocrinol.Metab. 2008 Aug;295(2):E313-22. 
 
(64) Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic 
reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004 Oct 
15;306(5695):457-461. 
77 
 
 
(65) Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat.Rev.Immunol. 2002 
Oct;2(10):725-734. 
 
(66) Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white 
adipose tissue. Br.J.Nutr. 2004 Sep;92(3):347-355. 
 
(67) Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, et al. Adipose tissue 
hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007 
Apr;56(4):901-911. 
 
(68) Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation 
of tissue function in obesity? Br.J.Nutr. 2008 Aug;100(2):227-235. 
 
(69) Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. 
Int.J.Obes.(Lond) 2009 Jan;33(1):54-66. 
 
(70) Regazzetti C, Peraldi P, Gremeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, et al. 
Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 2009 Jan;58(1):95-103. 
 
(71) Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of 
inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 2007 
Dec;455(3):479-492. 
 
(72) Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem.Pharmacol. 2002 
Sep;64(5-6):993-998. 
 
(73) Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase 
reactant for clinical practice. Eur.J.Clin.Invest. 1996 Jun;26(6):427-435. 
 
(74) Gabay C, Kushner I. Acute-phase proteins and other systemic responses to 
inflammation. N.Engl.J.Med. 1999 Feb 11;340(6):448-454. 
 
(75) Sjöholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, Lystig TC, et al. A 
microarray search for genes predominantly expressed in human omental adipocytes: 
adipose tissue as a major production site of serum amyloid A. J.Clin.Endocrinol.Metab. 2005 
Apr;90(4):2233-2239. 
 
(76) van Dielen FM, van't Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. 
Increased leptin concentrations correlate with increased concentrations of inflammatory 
markers in morbidly obese individuals. Int.J.Obes.Relat.Metab.Disord. 2001 Dec;25(12):1759-
1766. 
 
(77) Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, Stich V, et al. Serum amyloid A: 
production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 
2005 Mar;48(3):519-528. 
 
78 
 
(78) Gomez-Ambrosi J, Salvador J, Rotellar F, Silva C, Catalan V, Rodriguez A, et al. 
Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. 
Obes.Surg. 2006 Mar;16(3):262-269. 
 
(79) Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, et al. Acute-phase serum 
amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic 
complications. PLoS Med. 2006 Jun;3(6):e287. 
 
(80) Zhao Y, He X, Shi X, Huang C, Liu J, Zhou S, et al. Association between serum amyloid 
A and obesity: a meta-analysis and systematic review. Inflamm.Res. 2010 Feb 7. 
 
(81) Poitou C, Coussieu C, Rouault C, Coupaye M, Cancello R, Bedel JF, et al. Serum 
amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic 
status. Obesity (Silver Spring) 2006 Feb;14(2):309-318. 
 
(82) Poitou C, Divoux A, Faty A, Tordjman J, Hugol D, Aissat A, et al. Role of serum 
amyloid a in adipocyte-macrophage cross talk and adipocyte cholesterol efflux. 
J.Clin.Endocrinol.Metab. 2009 May;94(5):1810-1817. 
 
(83) Jernås M, Palming J, Sjöholm K, Jennische E, Svensson PA, Gabrielsson BG, et al. 
Separation of human adipocytes by size: hypertrophic fat cells display distinct gene 
expression. FASEB J. 2006 Jul;20(9):1540-1542. 
 
(84) Kisilevsky R, Tam SP. Acute phase serum amyloid A, cholesterol metabolism, and 
cardiovascular disease. Pediatr.Pathol.Mol.Med. 2002 May-Jun;21(3):291-305. 
 
(85) Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between 
serum amyloid A proteins and coronary artery disease: evidence from two distinct 
arteriosclerotic processes. Circulation 1997 Nov 4;96(9):2914-2919. 
 
(86) Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, et al. Serum 
amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: 
the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome 
Evaluation (WISE). Circulation 2004 Feb 17;109(6):726-732. 
 
(87) Delanghe JR, Langlois MR, De Bacquer D, Mak R, Capel P, Van Renterghem L, et al. 
Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart 
disease. Atherosclerosis 2002 Feb;160(2):471-476. 
 
(88) Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive 
protein, serum amyloid a and fibrinogen with prevalent coronary heart disease--baseline 
findings of the PAIS project. Atherosclerosis 2001 Jun;156(2):451-456. 
 
(89) Song C, Shen Y, Yamen E, Hsu K, Yan W, Witting PK, et al. Serum amyloid A may 
potentiate prothrombotic and proinflammatory events in acute coronary syndromes. 
Atherosclerosis 2009 Feb;202(2):596-604. 
 
79 
 
(90) Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum 
amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and 
atherosclerosis. Redox Rep. 2009;14(5):187-196. 
 
(91) Hatanaka E, Furlaneto CJ, Ribeiro FP, Souza GM, Campa A. Serum amyloid A-induced 
mRNA expression and release of tumor necrosis factor-alpha (TNF-alpha) in human 
neutrophils. Immunol.Lett. 2004 Jan 30;91(1):33-37. 
 
(92) Ribeiro FP, Furlaneto CJ, Hatanaka E, Ribeiro WB, Souza GM, Cassatella MA, et al. 
mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils 
and monocytes. Mediators Inflamm. 2003 Jun;12(3):173-178. 
 
(93) Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the 
release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood 
neutrophil. Biochem.Biophys.Res.Commun. 2000 Feb 16;268(2):405-408. 
 
(94) Peters T, Ausmeier K, Ruther U. Cloning of Fatso (Fto), a novel gene deleted by the 
Fused toes (Ft) mouse mutation. Mamm.Genome 1999 Oct;10(10):983-986. 
 
(95) van der Hoeven F, Schimmang T, Volkmann A, Mattei MG, Kyewski B, Ruther U. 
Programmed cell death is affected in the novel mouse mutant Fused toes (Ft). Development 
1994 Sep;120(9):2601-2607. 
 
(96) Jacobsson JA, Danielsson P, Svensson V, Klovins J, Gyllensten U, Marcus C, et al. Major 
gender difference in association of FTO gene variant among severely obese children with 
obesity and obesity related phenotypes. Biochem.Biophys.Res.Commun. 2008 Apr 
11;368(3):476-482. 
 
(97) Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide 
association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 
2007 Jun 1;316(5829):1341-1345. 
 
(98) Willer CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, Heid IM, et al. Six new loci 
associated with body mass index highlight a neuronal influence on body weight regulation. 
Nat.Genet. 2009 Jan;41(1):25-34. 
 
(99) Meyre D, Delplanque J, Chevre JC, Lecoeur C, Lobbens S, Gallina S, et al. Genome-wide 
association study for early-onset and morbid adult obesity identifies three new risk loci in 
European populations. Nat.Genet. 2009 Feb;41(2):157-159. 
 
(100) Peeters A, Beckers S, Verrijken A, Roevens P, Peeters P, Van Gaal L, et al. Variants in 
the FTO gene are associated with common obesity in the Belgian population. 
Mol.Genet.Metab. 2008 Apr;93(4):481-484. 
 
(101) Price RA, Li WD, Zhao H. FTO gene SNPs associated with extreme obesity in cases, 
controls and extremely discordant sister pairs. BMC Med.Genet. 2008 Jan 24;9:4. 
 
80 
 
(102) Hinney A, Nguyen TT, Scherag A, Friedel S, Bronner G, Muller TD, et al. Genome wide 
association (GWA) study for early onset extreme obesity supports the role of fat mass and 
obesity associated gene (FTO) variants. PLoS One 2007 Dec 26;2(12):e1361. 
 
(103) Andreasen CH, Stender-Petersen KL, Mogensen MS, Torekov SS, Wegner L, Andersen 
G, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on 
body fat accumulation. Diabetes 2008 Jan;57(1):95-101. 
 
(104) Haupt A, Thamer C, Machann J, Kirchhoff K, Stefan N, Tschritter O, et al. Impact of 
variation in the FTO gene on whole body fat distribution, ectopic fat, and weight loss. 
Obesity (Silver Spring) 2008 Aug;16(8):1969-1972. 
 
(105) Kring SI, Holst C, Zimmermann E, Jess T, Berentzen T, Toubro S, et al. FTO gene 
associated fatness in relation to body fat distribution and metabolic traits throughout a 
broad range of fatness. PLoS One 2008 Aug 13;3(8):e2958. 
 
(106) Fisher E, Schulze MB, Stefan N, Haring HU, Doring F, Joost HG, et al. Association of 
the FTO rs9939609 single nucleotide polymorphism with C-reactive protein levels. Obesity 
(Silver Spring) 2009 Feb;17(2):330-334. 
 
(107) Cha SW, Choi SM, Kim KS, Park BL, Kim JR, Kim JY, et al. Replication of genetic 
effects of FTO polymorphisms on BMI in a Korean population. Obesity (Silver Spring) 2008 
Sep;16(9):2187-2189. 
 
(108) Chang YC, Liu PH, Lee WJ, Chang TJ, Jiang YD, Li HY, et al. Common variation in the 
fat mass and obesity-associated (FTO) gene confers risk of obesity and modulates BMI in the 
Chinese population. Diabetes 2008 Aug;57(8):2245-2252. 
 
(109) Cornes BK, Lind PA, Medland SE, Montgomery GW, Nyholt DR, Martin NG. 
Replication of the association of common rs9939609 variant of FTO with increased BMI in an 
Australian adult twin population but no evidence for gene by environment (G x E) 
interaction. Int.J.Obes.(Lond) 2009 Jan;33(1):75-79. 
 
(110) Do R, Bailey SD, Desbiens K, Belisle A, Montpetit A, Bouchard C, et al. Genetic 
variants of FTO influence adiposity, insulin sensitivity, leptin levels, and resting metabolic 
rate in the Quebec Family Study. Diabetes 2008 Apr;57(4):1147-1150. 
 
(111) Gonzalez-Sanchez JL, Zabena C, Martinez-Larrad MT, Martinez-Calatrava MJ, Perez-
Barba M, Serrano-Rios M. Variant rs9939609 in the FTO gene is associated with obesity in an 
adult population from Spain. Clin.Endocrinol.(Oxf) 2009 Mar;70(3):390-393. 
 
(112) Hennig BJ, Fulford AJ, Sirugo G, Rayco-Solon P, Hattersley AT, Frayling TM, et al. 
FTO gene variation and measures of body mass in an African population. BMC Med.Genet. 
2009 Mar 5;10:21. 
 
81 
 
(113) Horikoshi M, Hara K, Ito C, Shojima N, Nagai R, Ueki K, et al. Variations in the HHEX 
gene are associated with increased risk of type 2 diabetes in the Japanese population. 
Diabetologia 2007 Dec;50(12):2461-2466. 
 
(114) Hubacek JA, Pitha J, Adamkova V, Lanska V, Poledne R. A common variant in the FTO 
gene is associated with body mass index in males and postmenopausal females but not in 
premenopausal females. Czech post-MONICA and 3PMFs studies. Clin.Chem.Lab.Med. 
2009;47(4):387-390. 
 
(115) Hunt SC, Stone S, Xin Y, Scherer CA, Magness CL, Iadonato SP, et al. Association of 
the FTO gene with BMI. Obesity (Silver Spring) 2008 Apr;16(4):902-904. 
 
(116) Jacobsson JA, Klovins J, Kapa I, Danielsson P, Svensson V, Ridderstråle M, et al. Novel 
genetic variant in FTO influences insulin levels and insulin resistance in severely obese 
children and adolescents. Int.J.Obes.(Lond) 2008 Nov;32(11):1730-1735. 
 
(117) Legry V, Cottel D, Ferrieres J, Arveiler D, Andrieux N, Bingham A, et al. Effect of an 
FTO polymorphism on fat mass, obesity, and type 2 diabetes mellitus in the French 
MONICA Study. Metabolism 2009 Jul;58(7):971-975. 
 
(118) Li H, Wu Y, Loos RJ, Hu FB, Liu Y, Wang J, et al. Variants in the fat mass- and obesity-
associated (FTO) gene are not associated with obesity in a Chinese Han population. Diabetes 
2008 Jan;57(1):264-268. 
 
(119) Ohashi J, Naka I, Kimura R, Natsuhara K, Yamauchi T, Furusawa T, et al. FTO 
polymorphisms in oceanic populations. J.Hum.Genet. 2007;52(12):1031-1035. 
 
(120) Omori S, Tanaka Y, Takahashi A, Hirose H, Kashiwagi A, Kaku K, et al. Association of 
CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 
diabetes in a Japanese population. Diabetes 2008 Mar;57(3):791-795. 
 
(121) Wing MR, Ziegler J, Langefeld CD, Ng MC, Haffner SM, Norris JM, et al. Analysis of 
FTO gene variants with measures of obesity and glucose homeostasis in the IRAS Family 
Study. Hum.Genet. 2009 Jun;125(5-6):615-626. 
 
(122) Tschritter O, Preissl H, Yokoyama Y, Machicao F, Haring HU, Fritsche A. Variation in 
the FTO gene locus is associated with cerebrocortical insulin resistance in humans. 
Diabetologia 2007 Dec;50(12):2602-2603. 
 
(123) Yajnik CS, Janipalli CS, Bhaskar S, Kulkarni SR, Freathy RM, Prakash S, et al. FTO gene 
variants are strongly associated with type 2 diabetes in South Asian Indians. Diabetologia 
2009 Feb;52(2):247-252. 
 
(124) Al-Attar SA, Pollex RL, Ban MR, Young TK, Bjerregaard P, Anand SS, et al. Association 
between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian 
multi-ethnic sample. Cardiovasc.Diabetol. 2008 Mar 13;7:5. 
 
82 
 
(125) Attaoua R, Ait El Mkadem S, Radian S, Fica S, Hanzu F, Albu A, et al. FTO gene 
associates to metabolic syndrome in women with polycystic ovary syndrome. 
Biochem.Biophys.Res.Commun. 2008 Aug 22;373(2):230-234. 
 
(126) Barber TM, Bennett AJ, Groves CJ, Sovio U, Ruokonen A, Martikainen H, et al. 
Association of variants in the fat mass and obesity associated (FTO) gene with polycystic 
ovary syndrome. Diabetologia 2008 Jul;51(7):1153-1158. 
 
(127) Doney AS, Dannfald J, Kimber CH, Donnelly LA, Pearson E, Morris AD, et al. The FTO 
gene is associated with an atherogenic lipid profile and myocardial infarction in patients 
with type 2 diabetes: a Genetics of Diabetes Audit and Research Study in Tayside Scotland 
(Go-DARTS) study. Circ.Cardiovasc.Genet. 2009 Jun;2(3):255-259. 
 
(128) Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruokonen A, et al. 
Common variation in the FTO gene alters diabetes-related metabolic traits to the extent 
expected given its effect on BMI. Diabetes 2008 May;57(5):1419-1426. 
 
(129) Sanghera DK, Ortega L, Han S, Singh J, Ralhan SK, Wander GS, et al. Impact of nine 
common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), 
IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC Med.Genet. 2008 Jul 
3;9:59. 
 
(130) Wehr E, Schweighofer N, Moller R, Giuliani A, Pieber TR, Obermayer-Pietsch B. 
Association of FTO gene with hyperandrogenemia and metabolic parameters in women 
with polycystic ovary syndrome. Metabolism 2009 Nov 13. 
 
(131) Zimmermann E, Kring SI, Berentzen TL, Holst C, Pers TH, Hansen T, et al. Fatness-
associated FTO gene variant increases mortality independent of fatness--in cohorts of 
Danish men. PLoS One 2009;4(2):e4428. 
 
(132) Cha S, Koo I, Park BL, Jeong S, Choi SM, Kim KS, et al. Genetic Effects of FTO and 
MC4R Polymorphisms on Body Mass in Constitutional Types. Evid 
Based.Complement.Alternat Med. 2009 Oct 11. 
 
(133) Chang YC, Liu PH, Lee WJ, Chang TJ, Jiang YD, Li HY, et al. Common variation in the 
fat mass and obesity-associated (FTO) gene confers risk of obesity and modulates BMI in the 
Chinese population. Diabetes 2008 Aug;57(8):2245-2252. 
 
(134) Tan JT, Dorajoo R, Seielstad M, Sim XL, Ong RT, Chia KS, et al. FTO variants are 
associated with obesity in the Chinese and Malay populations in Singapore. Diabetes 2008 
Oct;57(10):2851-2857. 
 
(135) Ng MC, Park KS, Oh B, Tam CH, Cho YM, Shin HD, et al. Implication of genetic 
variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 
diabetes and obesity in 6,719 Asians. Diabetes 2008 Aug;57(8):2226-2233. 
 
83 
 
(136) Karasawa S, Daimon M, Sasaki S, Toriyama S, Oizumi T, Susa S, et al. Association of 
the Common Fat Mass and Obesity Associated (FTO) Gene Polymorphism with Obesity in a 
Japanese Population. Endocr.J. 2010 Jan 6. 
 
(137) Grant SF, Li M, Bradfield JP, Kim CE, Annaiah K, Santa E, et al. Association analysis of 
the FTO gene with obesity in children of Caucasian and African ancestry reveals a common 
tagging SNP. PLoS One 2008 Mar 12;3(3):e1746. 
 
(138) Loos RJ, Bouchard C. FTO: the first gene contributing to common forms of human 
obesity. Obes.Rev. 2008 May;9(3):246-250. 
 
(139) Hakanen M, Raitakari OT, Lehtimäki T, Peltonen N, Pahkala K, Sillanmäki L, et al. 
FTO genotype is associated with body mass index after the age of seven years but not with 
energy intake or leisure-time physical activity. J.Clin.Endocrinol.Metab. 2009 Apr;94(4):1281-
1287. 
 
(140) Haworth CM, Carnell S, Meaburn EL, Davis OS, Plomin R, Wardle J. Increasing 
heritability of BMI and stronger associations with the FTO gene over childhood. Obesity 
(Silver Spring) 2008 Dec;16(12):2663-2668. 
 
(141) Hardy R, Wills AK, Wong A, Elks CE, Wareham NJ, Loos RJ, et al. Life course 
variations in the associations between FTO and MC4R gene variants and body size. 
Hum.Mol.Genet. 2010 Feb 1;19(3):545-552. 
 
(142) Lopez-Bermejo A, Petry CJ, Diaz M, Sebastiani G, de Zegher F, Dunger DB, et al. The 
association between the FTO gene and fat mass in humans develops by the postnatal age of 
two weeks. J.Clin.Endocrinol.Metab. 2008 Apr;93(4):1501-1505. 
 
(143) Wåhlen K, Sjölin E, Hoffstedt J. The common rs9939609 gene variant of the fat mass- 
and obesity-associated gene FTO is related to fat cell lipolysis. J.Lipid Res. 2008 
Mar;49(3):607-611. 
 
(144) Qi L, Kang K, Zhang C, van Dam RM, Kraft P, Hunter D, et al. Fat mass-and obesity-
associated (FTO) gene variant is associated with obesity: longitudinal analyses in two cohort 
studies and functional test. Diabetes 2008 Nov;57(11):3145-3151. 
 
(145) Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS, et al. The obesity-
associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 
2007 Nov 30;318(5855):1469-1472. 
 
(146) Stratigopoulos G, Padilla SL, LeDuc CA, Watson E, Hattersley AT, McCarthy MI, et al. 
Regulation of Fto/Ftm gene expression in mice and humans. 
Am.J.Physiol.Regul.Integr.Comp.Physiol. 2008 Apr;294(4):R1185-96. 
 
(147) Fredriksson R, Hägglund M, Olszewski PK, Stephansson O, Jacobsson JA, Olszewska 
AM, et al. The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation 
84 
 
and expressed in neurons of feeding-related nuclei of the brain. Endocrinology 2008 
May;149(5):2062-2071. 
 
(148) Fischer J, Koch L, Emmerling C, Vierkotten J, Peters T, Bruning JC, et al. Inactivation of 
the Fto gene protects from obesity. Nature 2009 Apr 16;458(7240):894-898. 
 
(149) Grunnet LG, Nilsson E, Ling C, Hansen T, Pedersen O, Groop L, et al. Regulation and 
function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose 
tissue. Diabetes 2009 Jul 8. 
 
(150) Zabena C, Gonzalez-Sanchez JL, Martinez-Larrad MT, Torres-Garcia A, Alvarez-
Fernandez-Represa J, Corbaton-Anchuelo A, et al. The FTO obesity gene. Genotyping and 
gene expression analysis in morbidly obese patients. Obes.Surg. 2009 Jan;19(1):87-95. 
 
(151) Villalobos-Comparan M, Teresa Flores-Dorantes M, Teresa Villarreal-Molina M, 
Rodriguez-Cruz M, Garcia-Ulloa AC, Robles L, et al. The FTO gene is associated with 
adulthood obesity in the Mexican population. Obesity (Silver Spring) 2008 Oct;16(10):2296-
2301. 
 
(152) Klöting N, Schleinitz D, Ruschke K, Berndt J, Fasshauer M, Tönjes A, et al. Inverse 
relationship between obesity and FTO gene expression in visceral adipose tissue in humans. 
Diabetologia 2008 Apr;51(4):641-647. 
 
(153) Grunnet LG, Brons C, Jacobsen S, Nilsson E, Astrup A, Hansen T, et al. Increased 
recovery rates of phosphocreatine and inorganic phosphate after isometric contraction in 
oxidative muscle fibers and elevated hepatic insulin resistance in homozygous carriers of the 
A-allele of FTO rs9939609. J.Clin.Endocrinol.Metab. 2009 Feb;94(2):596-602. 
 
(154) Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and Visceral Adipose 
Tissue FTO Gene Expression and Adiposity, Insulin Action, Glucose Metabolism, and 
Inflammatory Adipokines in Type 2 Diabetes Mellitus and in Health. Obes.Surg. 2009 Sep 9. 
 
(155) Wajchenberg BL, Nery M, Cunha MR, Silva ME. Adipose tissue at the crossroads in the 
development of the metabolic syndrome, inflammation and atherosclerosis. 
Arq.Bras.Endocrinol.Metabol. 2009 Mar;53(2):145-150. 
 
(156) Frayn KN. Visceral fat and insulin resistance--causative or correlative? Br.J.Nutr. 2000 
Mar;83 Suppl 1:S71-7. 
 
(157) Shoulders CC. The FTO (fat mass and obesity-associated) gene: big in adipocyte 
lipolysis? J.Lipid Res. 2008 Mar;49(3):495-496. 
 
(158) Sanchez-Pulido L, Andrade-Navarro MA. The FTO (fat mass and obesity associated) 
gene codes for a novel member of the non-heme dioxygenase superfamily. BMC Biochem. 
2007 Nov 8;8:23. 
 
85 
 
(159) Wardle J, Carnell S, Haworth CM, Farooqi IS, O'Rahilly S, Plomin R. Obesity associated 
genetic variation in FTO is associated with diminished satiety. J.Clin.Endocrinol.Metab. 2008 
Sep;93(9):3640-3643. 
 
(160) Timpson NJ, Emmett PM, Frayling TM, Rogers I, Hattersley AT, McCarthy MI, et al. 
The fat mass- and obesity-associated locus and dietary intake in children. Am.J.Clin.Nutr. 
2008 Oct;88(4):971-978. 
 
(161) Cecil JE, Tavendale R, Watt P, Hetherington MM, Palmer CN. An obesity-associated 
FTO gene variant and increased energy intake in children. N.Engl.J.Med. 2008 Dec 
11;359(24):2558-2566. 
 
(162) Haupt A, Thamer C, Staiger H, Tschritter O, Kirchhoff K, Machicao F, et al. Variation 
in the FTO gene influences food intake but not energy expenditure. 
Exp.Clin.Endocrinol.Diabetes 2009 Apr;117(4):194-197. 
 
(163) Speakman JR, Rance KA, Johnstone AM. Polymorphisms of the FTO gene are 
associated with variation in energy intake, but not energy expenditure. Obesity (Silver 
Spring) 2008 Aug;16(8):1961-1965. 
 
(164) Church C, Lee S, Bagg EA, McTaggart JS, Deacon R, Gerken T, et al. A mouse model 
for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS 
Genet. 2009 Aug;5(8):e1000599. 
 
(165) Olszewski PK, Fredriksson R, Olszewska AM, Stephansson O, Alsiö J, Radomska KJ, et 
al. Hypothalamic FTO is associated with the regulation of energy intake not feeding reward. 
BMC Neurosci. 2009 Oct 27;10:129. 
 
(166) Wardle J, Llewellyn C, Sanderson S, Plomin R. The FTO gene and measured food 
intake in children. Int.J.Obes.(Lond) 2009 Jan;33(1):42-45. 
 
(167) Johnson L, van Jaarsveld CH, Emmett PM, Rogers IS, Ness AR, Hattersley AT, et al. 
Dietary energy density affects fat mass in early adolescence and is not modified by FTO 
variants. PLoS One 2009;4(3):e4594. 
 
(168) den Hoed M, Westerterp-Plantenga MS, Bouwman FG, Mariman EC, Westerterp KR. 
Postprandial responses in hunger and satiety are associated with the rs9939609 single 
nucleotide polymorphism in FTO. Am.J.Clin.Nutr. 2009 Nov;90(5):1426-1432. 
 
(169) Sonestedt E, Roos C, Gullberg B, Ericson U, Wirfalt E, Orho-Melander M. Fat and 
carbohydrate intake modify the association between genetic variation in the FTO genotype 
and obesity. Am.J.Clin.Nutr. 2009 Nov;90(5):1418-1425. 
 
(170) Rampersaud E, Mitchell BD, Pollin TI, Fu M, Shen H, O'Connell JR, et al. Physical 
activity and the association of common FTO gene variants with body mass index and 
obesity. Arch.Intern.Med. 2008 Sep 8;168(16):1791-1797. 
 
86 
 
(171) Berentzen T, Kring SI, Holst C, Zimmermann E, Jess T, Hansen T, et al. Lack of 
association of fatness-related FTO gene variants with energy expenditure or physical 
activity. J.Clin.Endocrinol.Metab. 2008 Jul;93(7):2904-2908. 
 
(172) Corpeleijn E, Petersen L, Holst C, Saris WH, Astrup A, Langin D, et al. Obesity-related 
Polymorphisms and Their Associations With the Ability to Regulate Fat Oxidation in Obese 
Europeans: The NUGENOB Study. Obesity (Silver Spring) 2009 Oct 29. 
 
(173) Goossens GH, Petersen L, Blaak EE, Hul G, Arner P, Astrup A, et al. Several obesity- 
and nutrient-related gene polymorphisms but not FTO and UCP variants modulate 
postabsorptive resting energy expenditure and fat-induced thermogenesis in obese 
individuals: the NUGENOB study. Int.J.Obes.(Lond) 2009 Jun;33(6):669-679. 
 
(174) Jonsson A, Franks PW. Obesity, FTO gene variant, and energy intake in children. 
N.Engl.J.Med. 2009 Apr 9;360(15):1571-2; author reply 1572. 
 
(175) Meyre D, Proulx K, Kawagoe-Takaki H, Vatin V, Gutierrez-Aguilar R, Lyon D, et al. 
Prevalence of loss of function FTO mutations in lean and obese individuals. Diabetes 2009 
Oct 15. 
 
(176) Tanofsky-Kraff M, Han JC, Anandalingam K, Shomaker LB, Columbo KM, Wolkoff LE, 
et al. The FTO gene rs9939609 obesity-risk allele and loss of control over eating. 
Am.J.Clin.Nutr. 2009 Dec;90(6):1483-1488. 
 
(177) Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005 Apr 16-
22;365(9468):1415-1428. 
 
(178) Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The 
metabolic syndrome--a new worldwide definition. Lancet 2005 Sep 24-30;366(9491):1059-
1062. 
 
(179) Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. 
Diagnosis and management of the metabolic syndrome: an American Heart 
Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 
Oct 25;112(17):2735-2752. 
 
(180) Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. 
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes 
Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood 
Institute; American Heart Association; World Heart Federation; International 
Atherosclerosis Society; and international association for the Study of Obesity. Circulation 
2009 Oct 20;120(16):1640-1645. 
 
(181) Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk 
factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham 
Heart Study. Circulation 1983 May;67(5):968-977. 
 
87 
 
(182) Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist 
circumference and abdominal sagittal diameter: best simple anthropometric indexes of 
abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and 
women. Am.J.Cardiol. 1994 Mar 1;73(7):460-468. 
 
(183) Poirier P, Eckel RH. Obesity and cardiovascular disease. Curr.Atheroscler.Rep. 2002 
Nov;4(6):448-453. 
 
(184) Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially 
modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet 2004 Sep 11-17;364(9438):937-952. 
 
(185) Despres JP. Cardiovascular disease under the influence of excess visceral fat. 
Crit.Pathw Cardiol. 2007 Jun;6(2):51-59. 
 
(186) Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major 
risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998 Jun 
2;97(21):2099-2100. 
 
(187) Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 
2002 Jun 11;105(23):2696-2698. 
 
(188) Sowers JR. Obesity as a cardiovascular risk factor. Am.J.Med. 2003 Dec 8;115 Suppl 
8A:37S-41S. 
 
(189) Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and 
cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of 
the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease 
from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. 
Circulation 2006 Feb 14;113(6):898-918. 
 
(190) Despres JP. Targeting abdominal obesity and the metabolic syndrome to manage 
cardiovascular disease risk. Heart 2009 Jul;95(13):1118-1124. 
 
(191) Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are 
better discriminators of cardiovascular risk factors than BMI: a meta-analysis. 
J.Clin.Epidemiol. 2008 Jul;61(7):646-653. 
 
(192) Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, et al. The Predictive 
Value of Different Measures of Obesity for Incident Cardiovascular Events and Mortality. 
J.Clin.Endocrinol.Metab. 2010 Feb 3. 
 
(193) Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic 
view. Diabetes Metab.Rev. 1987 Apr;3(2):463-524. 
 
88 
 
(194) Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary 
heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without 
prior myocardial infarction. N.Engl.J.Med. 1998 Jul 23;339(4):229-234. 
 
(195) Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and 
prevention. J.Intern.Med. 2001 Mar;249(3):225-235. 
 
(196) Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery 
disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000 
Jul;23(7):962-968. 
 
(197) Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a 
national cohort of the U.S. population, 1971-1993. Diabetes Care 1998 Jul;21(7):1138-1145. 
 
(198) Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for 
cardiovascular disease: the Framingham study. Diabetes Care 1979 Mar-Apr;2(2):120-126. 
 
(199) Laakso M. Cardiovascular disease in type 2 diabetes from population to man to 
mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010 Feb;33(2):442-449. 
 
(200) Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, et al. The 
relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-
diabetic participants in the HOPE study: a prospective epidemiological analysis. 
Diabetologia 2005 Sep;48(9):1749-1755. 
 
(201) Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association 
of glycaemia with macrovascular and microvascular complications of type 2 diabetes 
(UKPDS 35): prospective observational study. BMJ 2000 Aug 12;321(7258):405-412. 
 
(202) Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-
analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. 
Ann.Intern.Med. 2004 Sep 21;141(6):421-431. 
 
(203) Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year 
cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein 
composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. 
Diabetologia 1993 Nov;36(11):1175-1184. 
 
(204) Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular 
complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. 
JAMA 1971 Nov;218(9):1400-1410. 
 
(205) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller 
ME, Byington RP, Goff DC,Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 
diabetes. N.Engl.J.Med. 2008 Jun 12;358(24):2545-2559. 
 
89 
 
(206) ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et 
al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. 
N.Engl.J.Med. 2008 Jun 12;358(24):2560-2572. 
 
(207) Jarrett RJ. Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart 
disease-chicken, egg or neither? Diabetologia 1984 Feb;26(2):99-102. 
 
(208) Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. 
Diabetes 1995 Apr;44(4):369-374. 
 
(209) Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. 
J.Clin.Endocrinol.Metab. 2001 Mar;86(3):965-971. 
 
(210) Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of 
insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration 
determined by nuclear magnetic resonance. Diabetes 2003 Feb;52(2):453-462. 
 
(211) Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 
2004 Jun;27(6):1496-1504. 
 
(212) Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. 
Diabetologia 2003 Jun;46(6):733-749. 
 
(213) Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med.Clin.North Am. 2004 
Jul;88(4):897-909, x. 
 
(214) Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. 
Nat.Clin.Pract.Endocrinol.Metab. 2009 Mar;5(3):150-159. 
 
(215) Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in 
insulin resistance and diabetes. Arch.Med.Res. 2005 May-Jun;36(3):232-240. 
 
(216) Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. 
Diabetes 2005 Jun;54(6):1615-1625. 
 
(217) Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in 
multiple forms of insulin resistance. Nature 2006 Apr 13;440(7086):944-948. 
 
(218) Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin 
resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. 
Arterioscler.Thromb.Vasc.Biol. 2004 May;24(5):816-823. 
 
(219) Shen GX. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria 
and NADPH oxidase. Can.J.Physiol.Pharmacol. 2010 Mar;88(3):241-248. 
 
(220) Willcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: 
key lessons from epidemiologic studies. Am.J.Cardiol. 2008 May 22;101(10A):75D-86D. 
90 
 
 
(221) Khaodhiar L, Cummings S, Apovian CM. Treating diabetes and prediabetes by 
focusing on obesity management. Curr.Diab Rep. 2009 Oct;9(5):348-354. 
 
(222) Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A. The potential influence of 
inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-
related complications in type 2 diabetes. J.Clin.Endocrinol.Metab. 2003 Jun;88(6):2422-2429. 
 
(223) Winkler G, Lakatos P, Salamon F, Nagy Z, Speer G, Kovacs M, et al. Elevated serum 
TNF-alpha level as a link between endothelial dysfunction and insulin resistance in 
normotensive obese patients. Diabet.Med. 1999 Mar;16(3):207-211. 
 
(224) Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship 
between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 
diabetes mellitus. Diabetes Res.Clin.Pract. 2001 May;52(2):119-123. 
 
(225) Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-
mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-
induced insulin resistance. Science 1996 Feb 2;271(5249):665-668. 
 
(226) Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, et al. Plasma 
tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. 
Eur.Heart J. 2002 Mar;23(5):376-383. 
 
(227) Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, et al. Disruption of tumor 
necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient 
mice. Atherosclerosis 2005 May;180(1):11-17. 
 
(228) Juhan-Vague I, Vague P. Hypofibrinolysis and insulin-resistance. Diabete Metab. 1991 
May;17(1 Pt 2):96-100. 
 
(229) Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic 
markers add to the predictive value of conventional risk factors for coronary heart disease 
and ischemic stroke? The Caerphilly Study. Circulation 2005 Nov 15;112(20):3080-3087. 
 
(230) Arikan H, Koc M, Tuglular S, Ozener C, Akoglu E. Elevated plasma levels of PAI-1 
predict cardiovascular events and cardiovascular mortality in prevalent peritoneal dialysis 
patients. Ren.Fail. 2009;31(6):438-445. 
 
(231) Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M, et al. Plasma 
angiotensinogen concentrations in obese patients. Am.J.Hypertens. 1997 Jun;10(6):629-633. 
 
(232) Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased 
adipose angiotensinogen gene expression in human obesity. Obes.Res. 2000 Jul;8(4):337-341. 
 
(233) Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. 
Nature 1998 Oct 22;395(6704):763-770. 
91 
 
 
(234) Peelman F, Waelput W, Iserentant H, Lavens D, Eyckerman S, Zabeau L, et al. Leptin: 
linking adipocyte metabolism with cardiovascular and autoimmune diseases. Prog.Lipid 
Res. 2004 Jul;43(4):283-301. 
 
(235) Sweeney G. Cardiovascular effects of leptin. Nat.Rev.Cardiol. 2010 Jan;7(1):22-29. 
 
(236) Winters B, Mo Z, Brooks-Asplund E, Kim S, Shoukas A, Li D, et al. Reduction of 
obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice. 
J.Appl.Physiol. 2000 Dec;89(6):2382-2390. 
 
(237) Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, et al. Sympathetic 
activation of leptin via the ventromedial hypothalamus: leptin-induced increase in 
catecholamine secretion. Diabetes 1999 Sep;48(9):1787-1793. 
 
(238) Knudson JD, Payne GA, Borbouse L, Tune JD. Leptin and mechanisms of endothelial 
dysfunction and cardiovascular disease. Curr.Hypertens.Rep. 2008 Dec;10(6):434-439. 
 
(239) Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin 
reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002 Nov 
26;106(22):2767-2770. 
 
(240) Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. 
Clin.Chim.Acta 2004 Jun;344(1-2):1-12. 
 
(241) Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: 
state of the art? Am.J.Physiol.Heart Circ.Physiol. 2007 Apr;292(4):H1655-63. 
 
(242) Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. 
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of 
type 2 diabetes. Nat.Genet. 2000 Sep;26(1):76-80. 
 
(243) Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, et al. Large-scale 
association studies of variants in genes encoding the pancreatic beta-cell KATP channel 
subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is 
associated with type 2 diabetes. Diabetes 2003 Feb;52(2):568-572. 
 
(244) Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. 
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. 
Nat.Genet. 2006 Mar;38(3):320-323. 
 
(245) McCarthy MI. Casting a wider net for diabetes susceptibility genes. Nat.Genet. 2008 
Sep;40(9):1039-1040. 
 
(246) Talmud PJ, Cooper JA, Palmen J, Lovering R, Drenos F, Hingorani AD, et al. 
Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in 
healthy middle-aged men. Clin.Chem. 2008 Mar;54(3):467-474. 
92 
 
 
(247) Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM. 
Cardiovascular disease risk prediction with and without knowledge of genetic variation at 
chromosome 9p21.3. Ann.Intern.Med. 2009 Jan 20;150(2):65-72. 
 
(248) Brautbar A, Ballantyne CM, Lawson K, Nambi V, Chambless L, Folsom AR, et al. 
Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification 
of coronary heart disease risk and implications for lipid-modifying therapy in the 
Atherosclerosis Risk in Communities study. Circ.Cardiovasc.Genet. 2009 Jun;2(3):279-285. 
 
(249) Clinical guidelines on the identification, evaluation, and treatment of overweight and 
obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and 
Treatment of Overweight in Adults. Am.J.Clin.Nutr. 1998 Oct;68(4):899-917. 
 
(250) Kopelman PG, Grace C. New thoughts on managing obesity. Gut 2004 Jul;53(7):1044-
1053. 
 
(251) Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? 
Diabetes Care 2008 Feb;31 Suppl 2:S269-77. 
 
(252) Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et 
al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with 
impaired glucose tolerance. N.Engl.J.Med. 2001 May 3;344(18):1343-1350. 
 
(253) Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. 
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 
N.Engl.J.Med. 2002 Feb 7;346(6):393-403. 
 
(254) Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. 
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of 
the Finnish Diabetes Prevention Study. Lancet 2006 Nov 11;368(9548):1673-1679. 
 
(255) Ratner RE, Diabetes Prevention Program Research. An update on the Diabetes 
Prevention Program. Endocr.Pract. 2006 Jan-Feb;12 Suppl 1:20-24. 
 
(256) Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise 
in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and 
Diabetes Study. Diabetes Care 1997 Apr;20(4):537-544. 
 
(257) Wing RR, Phelan S. Long-term weight loss maintenance. Am.J.Clin.Nutr. 2005 Jul;82(1 
Suppl):222S-225S. 
 
(258) Hill JO. Can a small-changes approach help address the obesity epidemic? A report of 
the Joint Task Force of the American Society for Nutrition, Institute of Food Technologists, 
and International Food Information Council. Am.J.Clin.Nutr. 2009 Feb;89(2):477-484. 
 
93 
 
(259) Astrup A, Grunwald GK, Melanson EL, Saris WH, Hill JO. The role of low-fat diets in 
body weight control: a meta-analysis of ad libitum dietary intervention studies. 
Int.J.Obes.Relat.Metab.Disord. 2000 Dec;24(12):1545-1552. 
 
(260) Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, et al. A low-
carbohydrate as compared with a low-fat diet in severe obesity. N.Engl.J.Med. 2003 May 
22;348(21):2074-2081. 
 
(261) Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, et al. A 
randomized trial of a low-carbohydrate diet for obesity. N.Engl.J.Med. 2003 May 
22;348(21):2082-2090. 
 
(262) Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, et al. The effects of 
low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year 
follow-up of a randomized trial. Ann.Intern.Med. 2004 May 18;140(10):778-785. 
 
(263) Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the 
Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk 
reduction: a randomized trial. JAMA 2005 Jan 5;293(1):43-53. 
 
(264) Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS,Jr, Brehm BJ, et al. Effects of 
low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-
analysis of randomized controlled trials. Arch.Intern.Med. 2006 Feb 13;166(3):285-293. 
 
(265) Bray GA. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. 
J.Clin.Endocrinol.Metab. 2008 Nov;93(11 Suppl 1):S81-8. 
 
(266) Blackburn GL, Phillips JC, Morreale S. Physician's guide to popular low-carbohydrate 
weight-loss diets. Cleve.Clin.J.Med. 2001 Sep;68(9):761, 765-6, 768-9, 773-4. 
 
(267) Freedman MR, King J, Kennedy E. Popular diets: a scientific review. Obes.Res. 2001 
Mar;9 Suppl 1:1S-40S. 
 
(268) Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, et al. The effects of 
low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year 
follow-up of a randomized trial. Ann.Intern.Med. 2004 May 18;140(10):778-785. 
 
(269) Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA. A randomized trial comparing a very 
low carbohydrate diet and a calorie-restricted low fat diet on body weight and 
cardiovascular risk factors in healthy women. J.Clin.Endocrinol.Metab. 2003 Apr;88(4):1617-
1623. 
 
(270) McLaughlin T, Carter S, Lamendola C, Abbasi F, Yee G, Schaaf P, et al. Effects of 
moderate variations in macronutrient composition on weight loss and reduction in 
cardiovascular disease risk in obese, insulin-resistant adults. Am.J.Clin.Nutr. 2006 
Oct;84(4):813-821. 
 
94 
 
(271) Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, et al. Effect of a 
mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation 
in the metabolic syndrome: a randomized trial. JAMA 2004 Sep 22;292(12):1440-1446. 
 
(272) Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, et al. Weight 
loss with a low-carbohydrate, Mediterranean, or low-fat diet. N.Engl.J.Med. 2008 Jul 
17;359(3):229-241. 
 
(273) Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, et al. Reduction in 
obesity and related comorbid conditions after diet-induced weight loss or exercise-induced 
weight loss in men. A randomized, controlled trial. Ann.Intern.Med. 2000 Jul 18;133(2):92-
103. 
 
(274) Irwin ML, Yasui Y, Ulrich CM, Bowen D, Rudolph RE, Schwartz RS, et al. Effect of 
exercise on total and intra-abdominal body fat in postmenopausal women: a randomized 
controlled trial. JAMA 2003 Jan 15;289(3):323-330. 
 
(275) Ross R, Janssen I, Dawson J, Kungl AM, Kuk JL, Wong SL, et al. Exercise-induced 
reduction in obesity and insulin resistance in women: a randomized controlled trial. 
Obes.Res. 2004 May;12(5):789-798. 
 
(276) Hill JO, Wyatt HR. Role of physical activity in preventing and treating obesity. 
J.Appl.Physiol. 2005 Aug;99(2):765-770. 
 
(277) National Nutrition Council. Finnish nutrient recommendations. 1st ed. Helsinki: 
Ministry of Agriculture and Forestry; 2005. 
 
(278) Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity 
and public health: updated recommendation for adults from the American College of Sports 
Medicine and the American Heart Association. Med.Sci.Sports Exerc. 2007 Aug;39(8):1423-
1434. 
 
(279) US Department of Health and Human Services, US Department of Agriculture. Dietary 
Guidelines for Americans 2005. Available at: http://www.healthierus.gov/dietaryguidelines. 
 
(280) Klem ML, Wing RR, McGuire MT, Seagle HM, Hill JO. A descriptive study of 
individuals successful at long-term maintenance of substantial weight loss. Am.J.Clin.Nutr. 
1997 Aug;66(2):239-246. 
 
(281) Schoeller DA, Shay K, Kushner RF. How much physical activity is needed to minimize 
weight gain in previously obese women? Am.J.Clin.Nutr. 1997 Sep;66(3):551-556. 
 
(282) Weinsier RL, Hunter GR, Desmond RA, Byrne NM, Zuckerman PA, Darnell BE. Free-
living activity energy expenditure in women successful and unsuccessful at maintaining a 
normal body weight. Am.J.Clin.Nutr. 2002 Mar;75(3):499-504. 
 
95 
 
(283) Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. Reduction of the plasma 
concentration of C-reactive protein following nine months of endurance training. Int.J.Sports 
Med. 2000 Jan;21(1):21-24. 
 
(284) Clement K, Langin D. Regulation of inflammation-related genes in human adipose 
tissue. J.Intern.Med. 2007 Oct;262(4):422-430. 
 
(285) Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J.Appl.Physiol. 
2005 Apr;98(4):1154-1162. 
 
(286) Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade 
inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in 
severely obese subjects. Am.J.Physiol.Endocrinol.Metab. 2006 May;290(5):E961-7. 
 
(287) Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, et al. 
Weight loss larger than 10% is needed for general improvement of levels of circulating 
adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. 
Eur.J.Endocrinol. 2008 Feb;158(2):179-187. 
 
(288) Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, et al. Reduction of 
inflammatory cytokine concentrations and improvement of endothelial functions in obese 
women after weight loss over one year. Circulation 2002 Feb 19;105(7):804-809. 
 
(289) Herder C, Peltonen M, Koenig W, Sutfels K, Lindström J, Martin S, et al. Anti-
inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study. 
Diabetologia 2009 Mar;52(3):433-442. 
 
(290) Hämäläinen H, Rönnemaa T, Virtanen A, Lindström J, Eriksson JG, Valle TT, et al. 
Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired 
glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia 2005 
Nov;48(11):2248-2253. 
 
(291) Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of 
macrophage infiltration and chemoattractant gene expression changes in white adipose 
tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005 
Aug;54(8):2277-2286. 
 
(292) Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is 
produced in isolated adipocytes, associated with adiposity and reduced after weight loss in 
morbid obese subjects. Int.J.Obes.(Lond) 2005 Jan;29(1):146-150. 
 
(293) Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, et al. Weight loss 
regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J. 
2004 Nov;18(14):1657-1669. 
 
96 
 
(294) Viguerie N, Vidal H, Arner P, Holst C, Verdich C, Avizou S, et al. Adipose tissue gene 
expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia 2005 
Jan;48(1):123-131. 
 
(295) Arvidsson E, Viguerie N, Andersson I, Verdich C, Langin D, Arner P. Effects of 
different hypocaloric diets on protein secretion from adipose tissue of obese women. 
Diabetes 2004 Aug;53(8):1966-1971. 
 
(296) Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS. Effects of a low-glycemic load 
diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 
2004 Nov 24;292(20):2482-2490. 
 
(297) van Dijk SJ, Feskens EJ, Bos MB, Hoelen DW, Heijligenberg R, Bromhaar MG, et al. A 
saturated fatty acid-rich diet induces an obesity-linked proinflammatory gene expression 
profile in adipose tissue of subjects at risk of metabolic syndrome. Am.J.Clin.Nutr. 2009 
Dec;90(6):1656-1664. 
 
(298) Kallio P, Kolehmainen M, Laaksonen DE, Pulkkinen L, Atalay M, Mykkänen H, et al. 
Inflammation markers are modulated by responses to diets differing in postprandial insulin 
responses in individuals with the metabolic syndrome. Am.J.Clin.Nutr. 2008 May;87(5):1497-
1503. 
 
(299) Christiansen T, Paulsen SK, Bruun JM, Pedersen SB, Richelsen B. Exercise-training 
versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in 
obese subjects.A 12-week randomized intervention-study. Am.J.Physiol.Endocrinol.Metab. 
2010 Jan 19. 
 
(300) Olson TP, Dengel DR, Leon AS, Schmitz KH. Changes in inflammatory biomarkers 
following one-year of moderate resistance training in overweight women. Int.J.Obes.(Lond) 
2007 Jun;31(6):996-1003. 
 
(301) Rokling-Andersen MH, Reseland JE, Veierod MB, Anderssen SA, Jacobs DR,Jr, Urdal 
P, et al. Effects of long-term exercise and diet intervention on plasma adipokine 
concentrations. Am.J.Clin.Nutr. 2007 Nov;86(5):1293-1301. 
 
(302) Tsukui S, Kanda T, Nara M, Nishino M, Kondo T, Kobayashi I. Moderate-intensity 
regular exercise decreases serum tumor necrosis factor-alpha and HbA1c levels in healthy 
women. Int.J.Obes.Relat.Metab.Disord. 2000 Sep;24(9):1207-1211. 
 
(303) Okita K, Nishijima H, Murakami T, Nagai T, Morita N, Yonezawa K, et al. Can exercise 
training with weight loss lower serum C-reactive protein levels? 
Arterioscler.Thromb.Vasc.Biol. 2004 Oct;24(10):1868-1873. 
 
(304) Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of 
interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after 
weight loss. J.Clin.Endocrinol.Metab. 2000 Sep;85(9):3338-3342. 
 
97 
 
(305) Bruun JM, Verdich C, Toubro S, Astrup A, Richelsen B. Association between measures 
of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis 
factor-alpha. Effect of weight loss in obese men. Eur.J.Endocrinol. 2003 May;148(5):535-542. 
 
(306) Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, et al. 
Effect of massive weight loss on inflammatory adipocytokines and the innate immune 
system in morbidly obese women. J.Clin.Endocrinol.Metab. 2007 Feb;92(2):483-490. 
 
(307) Salas-Salvado J, Bullo M, Garcia-Lorda P, Figueredo R, Del Castillo D, Bonada A, et al. 
Subcutaneous adipose tissue cytokine production is not responsible for the restoration of 
systemic inflammation markers during weight loss. Int.J.Obes.(Lond) 2006 Dec;30(12):1714-
1720. 
 
(308) Sheu WH, Chang TM, Lee WJ, Ou HC, Wu CM, Tseng LN, et al. Effect of weight loss 
on proinflammatory state of mononuclear cells in obese women. Obesity (Silver Spring) 2008 
May;16(5):1033-1038. 
 
(309) Muller TD, Hinney A, Scherag A, Nguyen TT, Schreiner F, Schafer H, et al. 'Fat mass 
and obesity associated' gene (FTO): no significant association of variant rs9939609 with 
weight loss in a lifestyle intervention and lipid metabolism markers in German obese 
children and adolescents. BMC Med.Genet. 2008 Sep 17;9:85. 
 
(310) Grau K, Hansen T, Holst C, Astrup A, Saris WH, Arner P, et al. Macronutrient-specific 
effect of FTO rs9939609 in response to a 10-week randomized hypo-energetic diet among 
obese Europeans. Int.J.Obes.(Lond) 2009 Aug 18. 
 
(311) Reinehr T, Hinney A, Toschke AM, Hebebrand J. Aggravating effect of INSIG2 and 
FTO on overweight reduction in a one-year lifestyle intervention. Arch.Dis.Child. 2009 Feb 
17. 
 
(312) Razquin C, Martinez JA, Martinez-Gonzalez MA, Bes-Rastrollo M, Fernandez-Crehuet 
J, Marti A. A 3-year intervention with a Mediterranean diet modified the association 
between the rs9939609 gene variant in FTO and body weight changes. Int.J.Obes.(Lond) 2009 
Nov 17. 
 
(313) Leibel RL. Energy in, energy out, and the effects of obesity-related genes. 
N.Engl.J.Med. 2008 Dec 11;359(24):2603-2604. 
 
(314) Cauchi S, Stutzmann F, Cavalcanti-Proenca C, Durand E, Pouta A, Hartikainen AL, et 
al. Combined effects of MC4R and FTO common genetic variants on obesity in European 
general populations. J.Mol.Med. 2009 May;87(5):537-546. 
 
(315) Jonsson A, Renstrom F, Lyssenko V, Brito EC, Isomaa B, Berglund G, et al. Assessing 
the effect of interaction between an FTO variant (rs9939609) and physical activity on obesity 
in 15,925 Swedish and 2,511 Finnish adults. Diabetologia 2009 Jul;52(7):1334-1338. 
 
98 
 
(316) Wong MY, Day NE, Luan JA, Chan KP, Wareham NJ. The detection of gene-
environment interaction for continuous traits: should we deal with measurement error by 
bigger studies or better measurement? Int.J.Epidemiol. 2003 Feb;32(1):51-57. 
 
(317) Mitchell JA, Church TS, Rankinen T, Earnest CP, Sui X, Blair SN. FTO Genotype and 
the Weight Loss Benefits of Moderate Intensity Exercise. Obesity (Silver Spring) 2009 Oct 1. 
 
(318) Rankinen T, Rice T, Teran-Garcia M, Rao DC, Bouchard C. FTO genotype is associated 
with exercise training-induced changes in body composition. Obesity (Silver Spring) 2010 
Feb;18(2):322-326. 
 
(319) Jacobsson JA, Riserus U, Axelsson T, Lannfelt L, Schiöth HB, Fredriksson R. The 
common FTO variant rs9939609 is not associated with BMI in a longitudinal study on a 
cohort of Swedish men born 1920-1924. BMC Med.Genet. 2009 Dec 9;10:131. 
 
(320) Vimaleswaran KS, Li S, Zhao JH, Luan J, Bingham SA, Khaw KT, et al. Physical activity 
attenuates the body mass index-increasing influence of genetic variation in the FTO gene. 
Am.J.Clin.Nutr. 2009 Aug;90(2):425-428. 
 
(321) Kolehmainen M, Salopuro T, Schwab US, Kekäläinen J, Kallio P, Laaksonen DE, et al. 
Weight reduction modulates expression of genes involved in extracellular matrix and cell 
death: the GENOBIN study. Int.J.Obes.(Lond) 2008 Feb;32(2):292-303. 
 
(322) Mager U, Kolehmainen M, de Mello VD, Schwab U, Laaksonen DE, Rauramaa R, et al. 
Expression of ghrelin gene in peripheral blood mononuclear cells and plasma ghrelin 
concentrations in patients with metabolic syndrome. Eur.J.Endocrinol. 2008 Apr;158(4):499-
510. 
 
(323) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 May 16;285(19):2486-2497. 
 
(324) Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. 
Diagnosis and management of the metabolic syndrome: an American Heart 
Association/National Heart, Lung, and Blood Institute scientific statement. 
Curr.Opin.Cardiol. 2006 Jan;21(1):1-6. 
 
(325) Diabetes mellitus. Report of a WHO Study Group. World Health.Organ.Tech.Rep.Ser. 
1985;727:1-113. 
 
(326) Uusitupa M, Peltonen M, Lindström J, Aunola S, Ilanne-Parikka P, Keinänen-
Kiukaanniemi S, et al. Ten-year mortality and cardiovascular morbidity in the Finnish 
Diabetes Prevention Study--secondary analysis of the randomized trial. PLoS One 2009 May 
21;4(5):e5656. 
 
99 
 
(327) Wang J, Kuusisto J, Vanttinen M, Kuulasmaa T, Lindström J, Tuomilehto J, et al. 
Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes 
in the Finnish Diabetes Prevention Study and are associated with impaired glucose 
regulation and impaired insulin secretion. Diabetologia 2007 Jun;50(6):1192-1200. 
 
(328) Stancakova A, Javorsky M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M. Changes 
in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 
6,414 Finnish men. Diabetes 2009 May;58(5):1212-1221. 
 
(329) World Health Organization. Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1 Diagnosis and classification of diabetes mellitus. 1999. 
 
(330) Laaksonen DE, Toppinen LK, Juntunen KS, Autio K, Liukkonen KH, Poutanen KS, et 
al. Dietary carbohydrate modification enhances insulin secretion in persons with the 
metabolic syndrome. Am.J.Clin.Nutr. 2005 Dec;82(6):1218-1227. 
 
(331) Kallio P, Kolehmainen M, Laaksonen DE, Kekäläinen J, Salopuro T, Sivenius K, et al. 
Dietary carbohydrate modification induces alterations in gene expression in abdominal 
subcutaneous adipose tissue in persons with the metabolic syndrome: the FUNGENUT 
Study. Am.J.Clin.Nutr. 2007 May;85(5):1417-1427. 
 
(332) Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose 
tolerance. Minimal-model approach. Diabetes 1989 Dec;38(12):1512-1527. 
 
(333) Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN. 
MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin 
sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes 
Technol.Ther. 2003;5(6):1003-1015. 
 
(334) Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. 
Clin.Chem. 1972 Jun;18(6):499-502. 
 
(335) Ohisalo JJ, Kaartinen JM, Ranta S, Mustajoki P, Hreniuk SP, LaNoue KF, et al. Weight 
loss normalizes the inhibitory effect of N6-(phenylisopropyl)adenosine on lipolysis in fat 
cells of massively obese human subjects. Clin.Sci.(Lond) 1992 Nov;83(5):589-592. 
 
(336) Rodbell M. Metabolism of Isolated Fat Cells. I. Effects of Hormones on Glucose 
Metabolism and Lipolysis. J.Biol.Chem. 1964 Feb;239:375-380. 
 
(337) Lappalainen T, Kolehmainen M, Schwab U, Pulkkinen L, Laaksonen DE, Rauramaa R, 
et al. Serum concentrations and expressions of serum amyloid A and leptin in adipose tissue 
are interrelated: the Genobin Study. Eur.J.Endocrinol. 2008 Mar;158(3):333-341. 
 
(338) Lappalainen TJ, Tolppanen AM, Kolehmainen M, Schwab U, Lindström J, Tuomilehto 
J, et al. The common variant in the FTO gene did not modify the effect of lifestyle changes on 
100 
 
body weight: the Finnish Diabetes Prevention Study. Obesity (Silver Spring) 2009 
Apr;17(4):832-836. 
 
(339) Kere J. Human population genetics: lessons from Finland. Annu.Rev.Genomics 
Hum.Genet. 2001;2:103-128. 
 
(340) Salmela E, Lappalainen T, Fransson I, Andersen PM, Dahlman-Wright K, Fiebig A, et 
al. Genome-wide analysis of single nucleotide polymorphisms uncovers population 
structure in Northern Europe. PLoS One 2008;3(10):e3519. 
 
(341) Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. 
Endocrinol.Metab.Clin.North Am. 2008 Sep;37(3):581-601, vii-viii. 
 
(342) Festa A, D'Agostino R,Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic 
subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance 
Atherosclerosis Study (IRAS). Circulation 2000 Jul 4;102(1):42-47. 
 
(343) Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 
diabetes. Diabetes Care 2004 Mar;27(3):813-823. 
 
(344) Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, Martin S, et al. Systemic 
immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from 
the Finnish Diabetes Prevention Study. Diabetes 2006 Aug;55(8):2340-2346. 
 
(345) Ryckman K, Williams SM. Calculation and use of the Hardy-Weinberg model in 
association studies. Curr.Protoc.Hum.Genet. 2008 Apr;Chapter 1:Unit 1.18. 
 
(346) Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg 
equilibrium. Am.J.Hum.Genet. 2005 May;76(5):887-893. 
 
(347) Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 
1996 Oct;6(10):986-994. 
 
(348) Alvehus M, Buren J, Sjostrom M, Goedecke J, Olsson T. The Human Visceral Fat Depot 
Has a Unique Inflammatory Profile. Obesity (Silver Spring) 2010 Feb 25. 
 
(349) Lunetta KL. Genetic association studies. Circulation 2008 Jul 1;118(1):96-101. 
 
(350) Newton-Cheh C, Hirschhorn JN. Genetic association studies of complex traits: design 
and analysis issues. Mutat.Res. 2005 Jun 3;573(1-2):54-69. 
 
(351) Thomas L. Retrospective Power Analysis. Conservation Biology 1997;11(1):276-280. 
 
(352) Thorn CF, Lu ZY, Whitehead AS. Regulation of the human acute phase serum amyloid 
A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and 
epithelial cell lines. Scand.J.Immunol. 2004 Feb;59(2):152-158. 
 
101 
 
(353) Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin stimulates 
proliferation and activation of human circulating monocytes. Cell.Immunol. 1999 May 
25;194(1):6-11. 
 
(354) Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma 
leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention 
study (WOSCOPS). Circulation 2001 Dec 18;104(25):3052-3056. 
 
(355) Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and 
prognosis in patients with established coronary atherosclerosis. J.Am.Coll.Cardiol. 2004 Nov 
2;44(9):1819-1824. 
 
(356) Hubacek JA, Stanek V, Gebauerova M, Pilipcincova A, Dlouha D, Poledne R, et al. A 
FTO variant and risk of acute coronary syndrome. Clin.Chim.Acta 2010 Apr 1. 
 
(357) He M, Cornelis MC, Franks PW, Zhang C, Hu FB, Qi L. Obesity genotype score and 
cardiovascular risk in women with type 2 diabetes mellitus. Arterioscler.Thromb.Vasc.Biol. 
2010 Feb;30(2):327-332. 
 
(358) Eriksson J, Lindström J, Valle T, Aunola S, Hämäläinen H, Ilanne-Parikka P, et al. 
Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes 
Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility 
of the lifestyle intervention programme. Diabetologia 1999 Jul;42(7):793-801. 
 
(359) Bassols J, Prats-Puig A, Vazquez-Ruiz M, Garcia-Gonzalez MM, Martinez-Pascual M, 
Avelli P, et al. Placental FTO expression relates to fetal growth. Int.J.Obes.(Lond) 2010 Mar 
30. 
 
(360) van den Berg L, de Waal HD, Han JC, Ylstra B, Eijk P, Nesterova M, et al. Investigation 
of a patient with a partial trisomy 16q including the fat mass and obesity associated gene 
(FTO): fine mapping and FTO gene expression study. Am.J.Med.Genet.A. 2010 
Mar;152A(3):630-637. 
 
(361) Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia 
induced apoptosis. J.Clin.Pathol. 2004 Oct;57(10):1009-1014. 
 
(362) Prins JB, Niesler CU, Winterford CM, Bright NA, Siddle K, O'Rahilly S, et al. Tumor 
necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes 1997 
Dec;46(12):1939-1944. 
 
(363) Jowett JB, Curran JE, Johnson MP, Carless MA, Goring HH, Dyer TD, et al. Genetic 
variation at the FTO locus influences RBL2 gene expression. Diabetes 2010 Mar;59(3):726-
732. 
 
(364) Liu YJ, Liu XG, Wang L, Dina C, Yan H, Liu JF, et al. Genome-wide association scans 
identified CTNNBL1 as a novel gene for obesity. Hum.Mol.Genet. 2008 Jun 15;17(12):1803-
1813. 
102 
 
 
(365) Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, et al. Common 
variants near MC4R are associated with fat mass, weight and risk of obesity. Nat.Genet. 2008 
Jun;40(6):768-775. 
 
(366) Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir 
A, et al. Genome-wide association yields new sequence variants at seven loci that associate 
with measures of obesity. Nat.Genet. 2009 Jan;41(1):18-24. 
 
(367) Patel SR, Hu FB. Short sleep duration and weight gain: a systematic review. Obesity 
(Silver Spring) 2008 Mar;16(3):643-653. 
  
(368) Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a 
major acute-phase protein, in normal and disease states. Curr.Opin.Hematol. 2000 
Jan;7(1):64-69. 
 
(369) Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N.Engl.J.Med. 2003 Aug 
7;349(6):583-596. 
 
 
 
 
 
 
 
 
 
 
Publications of the University of Eastern Finland
Dissertations in Health Sciences
isbn 978-952-61-0197-2
Publications of the University of Eastern Finland
Dissertations in Health Sciences
This study focused on the common 
sequence variation of the fat mass 
and obesity associated (FTO) gene.  It 
shows that also the individuals with 
a genetic predisposition to obesity 
benefit from lifestyle modification and 
lifestyle changes remain as an effec-
tive way to lose weight. Moreover, the 
gene expressions of FTO and serum 
amyloid A (SAA) were examined in 
subcutaneous adipose tissue of over-
weight and obese individuals with 
features of metabolic syndrome.
d
issertatio
n
s | 027 | T
iin
a L
a
ppa
la
in
en
 |  O
b
esity, L
ow
-grade In
fl
am
m
ation
 an
d C
ardiovascu
lar D
iseases
Tiina Lappalainen
Obesity, Low-grade 
Inflammation and 
Cardiovascular Diseases
Special Emphasis on Fat Mass and 
Obesity Associated (FTO) and
Serum Amyloid A (SAA) Genes
Tiina Lappalainen
Obesity, Low-grade Inflammation 
and Cardiovascular Diseases
Special Emphasis on Fat Mass and Obesity 
Associated (FTO) and Serum Amyloid A (SAA) 
Genes
